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Summary
Argonaute (Ago) proteins are viewed as key players in small RNA-guided gene silenc-
ing pathways in almost all eukaryotes. Small RNAs such as short interfering RNAs or
microRNAs guide Ago proteins to specific target RNAs resulting in mRNA decay or
translational silencing.
In miRNA-mediated silencing, Ago proteins associate with a member of the GW182
protein family in order to achieve efficient repression. GW182 proteins comprise a
N-terminal Ago-binding domain that is characterized by multiple GW-repeats and a
C-terminal silencing domain with several globular domains. GW182 hooks via its GW-
repeats into the PIWI domain of the Ago protein providing a binding platform for
downstream silencing events. Although the general principles underlying Ago-GW in-
teractions are well established, a detailed characterization of the GW-Ago association
has not been performed.
To elucidate the molecular basis for the interaction, we established a purification protocol
to obtained the desired recombinant proteins and used NMR spectroscopy, biochemical
and biophysical approaches as well as crosslinking to analyze affinities and binding prop-
erties of human Ago proteins to GW182 proteins.
Hence, we found exciting new aspects: First, the tryptophan flanking glycines are not
required and several other neighbors are accepted. Second, for efficient association only
several specific Trps engage in binding, which reside in fully unstructured protein envi-
ronments. Finally, we mapped the GW182 binding site on Ago and propose a model of
the Ago-GW182 interaction.
Thus, our results will contribute to the understanding of the mechanism of miRNA-
mediated gene silencing.
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1 Introduction
After the discovery of RNA interference (RNAi) in 1998 [62], fundamental insights into
the regulation of various cellular processes by small, non-coding RNAs (sRNAs) and
the underlying mechanism have been gained. The phenomenon of RNA-induced gene
silencing of complementary RNAs was first described in plants more than 20 years ago
[153][211]. Initially, gene silencing was supposed to be an adaptive defense in plants
against viruses and transposable elements [217] but soon, studies in Caenorhabditis elegans
(C. elegans) revealed that there are also endogenous causes responsible for post transcrip-
tional regulation that are well conserved throughout plants and animals [219][118][5]. To
date, RNAi is a powerful tool to repress specific genes [209]. It is applied in many fields,
ranging from basic research to medical therapy [197][202][69].
1.1 Classes of Small RNAs
During the last years, different species of sRNAs were identified that can be grouped into
three main classes based on their structure, biogenesis or mechanism. Common to all
classes is that, once processed, the sRNA is associated with a protein of the Argonaute
(Ago) protein family to exert its activity.
One class, short interfering RNAs (siRNAs), are excised by the ribonuclease (RNase) III
enzyme Dicer from long , double-stranded (ds) RNAs to ~21 nucleotide (nt) long RNA
duplexes. These precursor RNAs are either derived from exogenous sources like viruses
(exo-siRNAs) or endogenous sources (endo-siRNAs) e.g. transposable elements, natural
antisense transcripts or hairpin RNAs [38][70][106][161]. Dicer processing products are
characterized by 2 nt overhangs on both 3’ ends and phosphate groups on the 5’ ends
[62][81][46]. SiRNAs are typically composed of a guide strand, which is characterized by
perfect complementary to the target RNA and therefore also termed antisene strand and
a passenger (sense) strand [174]. According to the asymmetry rule, the strand with the
thermodynamically less stable 5’ end is selected for incorporation into Ago to form the
the RNA-induced silencing complex (RISC). The guide strand positions Ago on the tar-
get RNA by complementary base pairing. This leads to gene silencing through cleavage
of the bound mRNA provided that the Ago protein possesses endonucleolytic activity
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[190][109][176]. SiRNA biogenesis and function has been reviewed in detail [112][71][25].
Another class comprises P-element-induced wimpy testis (PIWI)-interacting RNAs (piR-
NAs). PiRNAs are processed in a Dicer-independent pathway to 24-31 nt long, single
stranded (ss) RNAs. They are typically associated with a member of the PIWI clade
of Ago proteins and have only been identified in animal germ cells [1][71][112]. Struc-
turally, this sRNA class is characterized by a 2’-O-methylation at their 3’ end [113][185].
However, the exact function of this modification is unclear. The biological significance
of piRNA relies mainly in the inactivation of mobile genetic elements [23].
The last class of sRNAs, microRNAs (miRNAs), will be discussed in detail in the fol-
lowing section.
1.1.1 MicroRNAs
MiRNAs are endogenous, ss sRNAs that regulate gene expression. They are ~21 nt in
length and expressed ubiquitously. After their discovery in C. elegans only two decades
ago in the labs of Ruvkun [219] and Ambros [118], miRNAs have now been shown to
play fundamental roles in many biological processes such as development, differentia-
tion, apoptosis and proliferation. They are highly conserved in many different species
ranging from plants, algae and viruses to mammals [78]. To date, more than 1000 miR-
NAs are annotated in humans and it is suggested that up to 60% of eukaryotic genes
underly miRNA-mediated regulation [66][114]. Based on that, miRNAs are viewed as
key-regulators of gene expression that are implicated in numerous diseases, offering great
potential for therapeutic trials.
MicroRNA Biogenesis
Most commonly, miRNAs are located as clusters and transcribed from a polycistronic
transcription unit in introns of protein-coding genes or untranslated regions (UTRs)
[121][25]. Transcription of miRNA genes is carried out by RNA-polymerase II, and
for some cases by RNA-polymerase III, resulting in hairpin-shaped primary miRNA-
transcripts (pri-miRNA)(Figure 1.1.1). Pri-miRNAs are typically several kilo bases long
with an imperfectly paired stem of ~33 bp and ss flanking ends. Like mRNAs, they
are polyadenylated at their 3’ ends and capped at their 5’ ends [112][15][122]. In the
canonical biogenesis pathway (Figure 1.1.1 A, B), pri-miRNas are cleaved in a first
step by the microprocessor complex, containing the RNase III-enzyme Drosha and its
cofactor DGCR8 in humans (Pasha in Drosophila melanogaster (D. melanogaster) and
C. elegans) [40][77][83]. DGCR8 recognizes the ss ends and assists Drosha in excising
the stem loop to create the precursor-miRNAs (pre-miRNAs) with characteristic 2 nt
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overhangs at the 3’ end and a phosphate group at the 5’ end typical for RNase III pro-
cessing [119]. The pre-miRNA is subsequently exported to the cytoplasm by Exportin 5
[12][136][226].
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Figure 1.1.1: MiRNA biogenesis pathway. A) Canonical miRNA biogenesis pathway from non-
coding RNA transcripts. B) Canonical pathway of intronic miRNAs. C) Drosha-independent non-
canonical pathway for biogenesis of mirtrons from introns (adopted from[112]).
3
1 Introduction
However, alternative pathways were found in vertebrates and invertebrates, which pro-
duce miRNA precursors resembling pre-miRNAs independent of the microprocessor com-
plex. These precursors termed mirtrons are excised by the splicing machinery (Fig-
ure 1.1.1 C) and then enter the canonical miRNA processing pathway [162][180]. Re-
cently, other non canonical pathways have been described with sRNAs derived from
tRNAs [3] or small nucleolar RNAs (snoRNAs) [49].
A second processing step is carried out in the cytoplasm that involves Dicer and its co-
factors TRBP an/or PACT (Loquacious (LOQS) in D. melanogaster) [32][63][120][184].
Dicer liberates a ~21 nt long ds miRNA with 2 nt overhangs at their 3’ ends and a
phosphate group at the 5’ end from the stem loop [95][46]. However, recent observations
also suggest a Dicer-independent maturation step of miRNA that required catalysis by
Ago2 [30][34].
Usually, the miRNA passenger strand (miRNA*) is degraded, whereas the mature miRNA
is incorporated into an Ago protein to form the micro-ribonucleoprotein particle (miRNP)
or miRNA-induced-silencing complex (miRISC) and directs effector proteins to the RNA
target.
Given the strong and general impact of miRNA-mediated gene regulation, the levels of
miRNAs is crucial for the cell and have to be controlled tightly. MiRNA metabolism
is regulated by multiple proteins at various levels e.g. on the level of transcription or
posttranscriptionally by influencing processing steps, nuclear export or miRISC stability
[207][115][220].
MicroRISC Assembly
MiRISCs are the effector complexes mediating mRNA repression. The core proteins
comprising the miRISC are a miRNA bound Ago protein and a protein of the GW182
family [59].
In humans, active RISC formation is assisted by Ago, Dicer, TRBP and/or PACT
(in flies Dicer1, LOQS and Ago1), together forming the RISC loading complex (RLC)
[32][80][120][140][139][76]. For RISC assembly, RNA duplexes generated by Dicer pro-
cessing are separated and one strand is selected for Ago loading according to the asym-
metry rule [190][109][176]. This selection is sensed by Dicer or by one of its cofactors
[132][133][156]. It is assumed that, after processing by Dicer, TRBP associates with the
more stable duplex end, while the other end interacts with Ago [204][132].
MiRNP assembly is facilitated by the endonucleolytic (slicer) activity of Ago2 [41] which
requires perfect complementary of the RNA duplex. This is the case for siRNAs, how-
ever, most miRNAs contain mismatches that prevent cleavage. Similarly, Ago1, 3 and 4
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lack slicer activity and are nevertheless loaded with ssRNAs [146]. Thus, further mech-
anisms must exist that support RISC loading.
The endoribonuclease C3PO was shown to facilitate siRNA-initiated RISC activation
in mammals and D. melanogaster [134][225]. A slicer independent mechanism involving
RNA helicases was suggested to play a role in RISC assembly [178] in an ATP-dependent
manner [159][228] by unwinding the duplex. More recently, the Hsc70/Hsp90 chaper-
one machinery was proposed to function in RISC assembly by inducing conformational
changes in the Ago structure in an ATP-dependent way, thereby facilitating Ago loading
[97] [102][149]. However, the detailed molecular mechanism of RISC loading is elusive.
1.2 Argonaute Proteins - the Central Components of
MicroRISCs
Ago proteins are indispensable for miRNA/siRNA-mediated gene silencing [199]. They
directly bind miRNAs, thereby recruiting effector complexes to the target mRNA which
mediate regulation of gene expression. Thus, Ago proteins constitute the central com-
ponents of miRISCs.
The protein family was first described in Arabidopsis thaliana [150] and is named after
an Arabidopsis thaliana mutant, which phenotypically resembled a small squid termed
argonaut [11]. Ago proteins are highly conserved in almost all kingdoms of life ranging
from archaea and bacteria to plants and higher eukaryotes [24][89]. Organisms comprise
multiple copies of Ago genes, e.g. eight in humans, five in D. melanogaster and 27 in
C. elegans with different expression profiles and substrate specificities [96].
The Ago protein family is divided into three clades: germline specific PIWI proteins
that bind piRNAs, ubiquitously expressed Ago proteins interacting with siRNAs and
miRNAs and the worm-specific WAGO subfamily [127][24][227][60].
Humans have eight Ago proteins. Four of them belong to the PIWI subfamily, named
HIWI1, HIWI2, HIWI3 and HILI, whereas the other four belong to the Ago class named
Ago1, Ago2, Ago3 and Ago4. The functional difference between the four Ago proteins
is unclear, however, Ago2 is the only protein possessing cleavage activity.
1.2.1 Argonaute Functional Domains
Ago functions as effector protein in miRNA/siRNA-mediated gene silencing, thus, it
must bind the miRNA/siRNA in a way suitable for RNA target recognition. Initial
studies on prokaryotic Ago proteins revealed a bilobal architecture comprising four glob-
ular domains: N, PIWI/Argonaute/Zwille (PAZ), middle (MID) and PIWI [196] (Fig-
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ure 1.2.1). The guide DNA spans between both lobes with its 3’ end anchored in the PAZ
and the 5’ end anchored to the MID domain [138][230][215]. Investigation of isolated
domains from eukaryotic species allowed to determine nucleotide binding specificity and
eukaryote-specific insertions [129][64][14][13].
Recently, two groups succeeded to crystallize full length human Ago2 providing struc-
tural insights into the mechanism of eukaryotic miRNA function [188][47]. The overall
architecture resembles prokaryotic structures with a bilobal shape and a central cleft for
miRNA/siRNA binding. The individual domains align well with the available structures,
however, the relative position of the lobes differ from their prokaryotic counterparts. The
authors also observe additional secondary structures and extended loops, which are pro-
posed to function in RNA binding, target RNA recognition or interaction with other
proteins.
Figure 1.2.1: Crystal structure of Ago2. Ago2 crystal structure (PDB: 4EI3) [188] with its func-
tional domains N (yellow), PAZ (blue), MID (purple) and PIWI (green) indicated. Bound miRNA is
colored in black.
The N-terminal domain comprises the highest sequential variety in comparison to ho-
mologues (for alignment see appendix).
The PAZ domain resembles an oligosaccharide/oligonucleotide-binding domain or Sm-
fold domain. As shown before [137][129], conserved residues of a hydrophobic pocket
specifically recognize the 3’ dinucleotide of the miRNA/siRNA, which result from Dicer
cleavage. The last base stacks against F294 and remaining interactions are mainly me-
diated by the phosphate backbone and are thus sequence independent [47].
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The MID domain reveals a fold similar to sugar-binding domain of the lac-repressor. As
reported previously [14][64], the MID domain of human full length Ago2 forms a pocket
for tethering the 5’ phosphate of the miRNA/siRNA. Several residues (Y529, K533,
Q545, C546 K566, K570, R812, A859) were identified that are essential for binding. In
contrast to prokaryotic structures, the authors did not find a magnesium ion coordinated
in the pocket [188][47]. Sequencing studies showed that human miRNA more frequently
exhibit an uracil or adenine at their 5’ end [90]. This was confirmed by Frank et al.
who demonstrated that adenine and uracil nucleotides are indeed kinetically preferred
using nuclear magnetic resonance (NMR) titration experiments with the recombinant
human Ago2 MID domain [64]. However, MID domains of other species show different
nucleotide preferences [70][106][147][179]. Thus, the specificity for the 5’ nucleotide is
provided by the MID domain.
Besides recognition of the miRNA ends, Ago2 offers extensive interactions with the phos-
phate backbone, thereby positioning the seed region (nt 2-8) of the miRNA suitable for
target binding [188][47].
The PIWI domain comprises a RNase H fold [196]. RNase H usually catalyses hydrol-
ysis of RNA in RNA-DNA duplices. Accordingly, prokaryotic Ago proteins were found
to be DNA-guided RNase [138][230]. In contrast, Ago proteins of higher species possess
cleavage activity towards RNA-RNA duplexes. The catalytic center of RNase H contains
an aspartate (Asp)-Asp-glutamate (Glu)/Asp triad with two coordinated divalent metal
ions required for cleavage activity [158]. Similarly, RISC-mediated cleavage is dependent
on the presence of divalent metal ions, however, the active site differs. Initially the active
site was assumed to comprises a catalytic Asp-Asp-histidine (His) triad [130][191], which
was shown to be required but not sufficient for cleavage activity [130][145]. In humans,
Ago2 and Ago3 offer the Asp-Asp-His motif but only Ago has cleavage activity towards
fully complementary targets and is therefore referred to as ’slicer’ [128]. Recently, a
crystal structure of the ternary Kluyveromyces polysporus Ago complex revealed a fourth
residue that pluggs into the catalytic triad thereby completing the active center of Ago
to a catalytic DEDX tetrad [152]. The PIWI domain has been implicated in binding
GW182, supported by the Ago2 crystal structure with two tryptophans (Trps) bound
to the PIWI domain [203][126][188]. GW182 proteins were demonstrated to act as key
players in miRNA-mediated gene silencing using Ago as a platform to trigger miRNA
function [28][57][17]. The interaction of GW182 proteins with Ago and the functional
implications will be discussed in the next section in detail.
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1.3 The GW182 Protein Family - Argonaute Interaction
Partners
In animals, Ago proteins bind miRNAs to mediate gene silencing [59]. Most miRNAs are
not fully complementary to their target RNAs, thus, cleavage by Ago2 cannot be exerted
[6]. A post transcriptional silencing mechanism involving the GW182 protein family was
intensively studied during the past years and it emerged that GW182 proteins directly
interact with Ago proteins thereby recruiting downstream factors leading to translational
repression and mRNA degradation [235][231][224][201][175][126][92][57][51][43][31][28][17].
GW182 proteins were first described by Eystathioy et al. one decade ago. The researchers
observed a 182 kDa protein containing multiple glycine (Gly)-Trp-repeats (GW-repeats)
in a patients autoimmune serum suffering from motor and sensory neuropathy. The
protein was shown to accumulate in discrete cytoplasmic speckles termed GW-bodies
associated with mRNA and a role in posttranscriptional regulation of gene expression
was suggested [55]. A subsequent report gave evidence that GW-bodies coincide with
cytoplasmic structures containing markers of the mRNA degradation pathway [56]. The
link to miRNA-mediated gene silencing was later established when the GW182 homo-
logue AIN-1 was shown to interact with the miRISC in processing bodies [44]. A short
time later, GW182 was demonstrated to be essential for miRNA-mediated gene-silencing
[175] and a physical interaction between Ago and GW182 was proven [131][146].
1.3.1 GW182 Domain Organization
Three GW182 paralog were identified in vertebrates termed trinucleotide repeat con-
taining protein 6 (TNRC6) A (corresponding to GW182), B and C. Insects comprise a
single ortholog (GW182 or Gawky) [8]. Vertebrates and insect proteins share a similar
domain organization. All proteins feature a N-terminal Ago-binding region, an ubiquitin
associated (UBA)-like domain, a glutamine (Q)-rich region, a PABP-interacting motif
2 (PAM2) motif and a C-terminal RNA recognition motif (Figure 1.7.1). Multiple se-
quence alignment shows a high sequence variety with highly conserved stretches in the
Ago-binding region, UBA domain, PAM2 motif and RRM (see appendix) [43][54]. The
proteins have a molecular weight of about 180 kDa and are mainly disordered except for
two globular domains: the UBA-like domain and a RRM.
UBA domains are common sequence motifs of about 45 amino acids (aa) usually oc-
curing in proteins involved in the ubiquitin/proteasom pathway, DNA repair or cell
growth. They fold into a three helix bundle with large hydrophobic patches which form
the interface for binding mono- or polyubiquinated substrates [200][21]. The NMR solu-
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tion structure of the TNRC6C UBA-like domain corresponds to the canonical UBA fold
(PDB: 2DKL; Zhao et al. 2006, data not published). GW182 was proposed to mediate
the interaction to the E3 ubiquitin ligase identified by differential display (EDD) via
UBA domain dimerization and PAM2 binding [198].
Figure 1.3.1: Schematic of TNRC6B domain organization. Schematic representation of the
TNRC6B domain composition and boundaries. The basic organization is shared for vertebrate and
insect proteins. Domains are color coded as follows: green: GW-rich region, dark green: GW-rich
conserved motif I and II, yellow: UBA domain, purple: Q-rich-region, dark gray: PAM2 motif, red:
RRM domain, linker region: gray.
RRMs usually bind single stranded RNA and adopt a fold containing four anti-parallel
beta strands and two alpha helices [35]. The structure of the D. melanogaster GW182
RRM revealed a canonical fold with an additional C-terminal helix. The lack of RNA
binding features suggests that the RRM is rather involved in protein-protein interactions
[53]. The exact function of the RRM domain has not been characterized.
The PAM2 motif is responsible for association with the polyadenylate binding protein
1 (PABPC1) and is embedded in a disordered part of the proteins C-terminus between
the UBA-like domain and the RRM domain. The crystal structure of PAM2 bound to
the C-terminal domain of PABPC1 gave first structural insights into GW182 function
[101][58][231]. As mentioned above, the PAM2 domain is also responsible for EDD bind-
ing via its PABC domain.
N-terminally to the PAM2 motif, GW182 proteins possess a Q-rich region, which is nec-
essary for P-body localization but dispensable for the silencing activity [8][117].
Trp-motifs in the C-terminal, middle and N-terminal region of GW182 have been im-
plicated in recruiting effector proteins as the CCR4-Not complex responsible for mRNA
repression [29][57][27][28]. One report identified two CCR4-Not interaction motifs (CIM1
and CIM2) in the M1 and C-terminal region that are conserved in mammals [57]. In
parallel it was published that CCR4-Not binds to several Trp-repeats in the M2 and
C-terminal region [28]. The authors suggested that the Trp-motifs form a bipartite do-
main with autonomous silencing activity [57][51][235]. In contrast to the C-terminal
Trp-motifs, several studies demonstrated that GW-repeats in the N-terminus of GW182
are important for the interaction with Ago [8][203].
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1.4 Argonaute - GW-protein Interaction
1.4.1 Mapping of Ago and GW182 Binding Sites
The N-terminal GW-repeat containing region of GW182 proteins was demonstrated to be
neccessary and sufficient for the interaction with the PIWI domain of Ago [45][8][126][203].
Residues important for binding GW182 in Ago were identified by mutational studies
in human Ago2 and D. melanogaster Ago1 by different groups [51][203][52][13]. Two
hotspots were identified that both abrogated GW182 binding upon mutation. One re-
sides in the MID domain compassing the 5’ binding pocket, the second one clusters
around the two Trp binding sites identified by Schirle et al. [188].
MiRNA binding was only affected by mutation of residues in the 5’ binding pocket.
This suggests that GW182 binding either depends on miRNA binding or mutations in
the MID domain induce changes that prevent binding. This results give evidence that
GW182 interacts with spots approximately in the MID/PIWI domain of the Ago pro-
tein. Interestingly, not all Ago proteins are capable of GW182 binding, as shown for
D. melanogaster Ago2 or PIWI-like proteins [8][148]. Therfore, GW182 binding capac-
ity might be limited to Ago proteins functioning in the miRNA pathway.
Defining the binding site of Ago on GW182 proteins emerged to be more challenging.
Species and method-specific difference in binding sites and affinities did not allow to draw
a clear picture. Consistently, all reports showed that the N-terminal GW182 region is
necessary and sufficient for Ago binding [8][203][45][117][126][201][4][235], although Lian
et al. observed additional Ago affinity for GW-repeats in the C-terminus [126]. Shortly
after locating the binding region, GW-repeats emerged as the key determinants for effi-
cient binding and a high affinity region termed Ago-hook was mapped, which is however
not conserved in all GW182 homologs [203]. Further studies reported that conserved
motif I, II or the Ago hook provide major binding sites depending on the species and
paralog, with additional repeats strengthening the interaction [8][51][117][4].
1.4.2 GW-repeats as Conserved Argonaute Binding Hooks
The importance of GW-repeats in miRNA-mediated gene silencing was recognized after
the discovery of GW182 [55]. This protein quickly evolved to a key component in the
miRNA pathway recruiting effector proteins to the mRNA by binding Ago through GW
repeats [45][8][126][203][203]. However, GW182 is not the only protein using GW-repeats
to associate with Ago proteins.
In parallel to the investigation of GW182-Ago binding, proteins involved in transcrip-
tional gene silencing (TGS) by the RNA-induced transcriptional silencing (RITS) com-
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plex in fission yeast were shown to interact with Ago in a similar way. The RITS
constitutes an Ago protein, the chromodomain protein Chp1 and Tas3, which mediates
transcriptional silencing [213][22]. The authors revealed an interaction module within
Tas3 with high sequence conservation to the GW-repeat containing Ago-hook of GW182.
This motif was essential for TGS and mutation of a single G or W residue abolished bind-
ing [167][203].
In plants, a RNAi-related mechanism known as RNA-directed DNAmethylation (RdDM)
silences target DNAs by methylation involving nuclear RNA polymerases that synthe-
size or bind scaffold RNAs [20][233]. Pol V largest subunit NRPE1 comprises a specific
GW-repeat containing C-terminus that interacts with Ago4 and is required for Pol V
function [45][172][125]. In the same pathway, an SPT5 homolog (KTF1) was shown to
link PolV transcription with Ago4 mediated via GW-repeat interaction [86]. Further, the
tetrahymenia Ago protein was shown to interact with two GW-repeat proteins termed
Wag1p and CnjBp, thereby promoting genome rearrangement [7]. Recently, the inter-
action between the GW-repeat containing prion protein PrP (C) and human Ago2 was
established. It was proposed that the prion protein facilitates formation or stability of
miRISC effector complexes on multivesicular bodies (MVBs) and that the prion protein
is required for efficient repression [72].
GW-proteins were also implicated in pathogen defense against the host RNAi machin-
ery in plants. Two independent studies provide evidence that viruses use own proteins
containing Ago-hooks to hijack the host Ago silencing system and are essential for viral
suppressor of RNA silencing (VSR) function [2][74].
Overall, those reports indicate that GW repeats function in numerous proteins of diver-
gent species as evolutionary conserved Ago binding platforms.
1.4.3 GW-repeat Binding Mode
GW-proteins are known to serve as universal Ago binding platforms. In posttranscrip-
tional mRNA regulation, short linear interaction motifs (SLiMs), like the GW-repeats,
are common sequence features in a variety of pathways [42][18][208][67]. SLiMs have a
length of about 6-11 aa and are typically found in disordered protein regions. To char-
acterize the binding mode of GW182 GW-repeats it might help to examine the results
obtained for related SLiMs besides investigation of GW182-Ago interaction data.
Several studies gave evidence that Trp and its neighbor Gly are crucial for efficient inter-
action of GW-repeats and Ago [203][45][4][201]. Moreover, investigation of NRPE1 and
TNRC6A GW-repeats showed little sequence conservation except for the GW-repeats,
however, the aa composition was biased with a high content of Gly, serine (Ser), Trp
11
1 Introduction
medium content of Glu, Asp, asparagine (Asn) and to a little extent cystein (Cys),
phenylalanine (Phe), His, methionine (Met) and tyrosine (Tyr) [45]. Due to the low con-
servation score and variability of GW-repeats in number and length, it is very difficult to
predict GW-repeat containing proteins. Using an bioinformatical approach, Karlowski
et al. developed a tool to detect GW-motifs in proteins [234]. They find that the aa
embedding the Trp are mainly of small, hydrophilic and charged nature and suggest
that this might facilitate surface accessibility of the Trp [103].
The Ago2 crystal structure by Schirle et al. provided hints on the binding mode of
GW182 to Ago. The authors found two adjacent Trp binding pockets on the surface of
the PIWI domain and concluded that GW182 bind to those sites by a tandem Trp motif
[188].
However, the binding mode of GW-repeats remains unclear and might also be distinct
for different proteins. Thus, it is difficult to exactly predict whether and how strong a
protein interacts with Ago.
There are not only GW-motifs but also well known Trp motifs comprising other neigh-
bors than Gly, thereby exerting a completely distinct function. Thus, it is important
to discriminate between GW-motifs and related Trp motifs [195][28][57]. On the other
hand, there are motifs comprising other aromatic residues instead of Trp, which are also
embedded in low complexity regions [65][104].
Together, SLiMs and in particular Trp-containing motifs were shown to interact with
an increasing number of proteins involved in multiple processes. Defining the context
of the Trp required for efficient binding will help to shed light on this complex protein
network.
1.5 Subcellular Localization
Ago proteins are specifically distributed in the cell [128][145][182]. 15-20% of the Ago
protein was observed to localize to the nucleus whereas the remainder resides in the
cytoplasm [160]. From the cytoplasmic pool, a minor part accumulates in processing
bodies (P-bodies) [124].
P-bodies are dynamic cytoplasmic mRNP aggregates that harbor translationally inac-
tive mRNAs [9]. They assemble around components that function in posttranscriptional
decay, processing and transport of mRNA, e.g. they are enriched in GW182 which is
the reason why P-bodies are also named GW-bodies. In the following, P-bodies or GW-
bodies will be termed P/GW-bodies. P/GW-bodies can be detected microscopically
and are clearly distinguished from other foci as stress granules by their specific protein
markers [194][50][166]. P/GW-body formation requires mRNAs, however, their repres-
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sion and storage is a reversible process [9]. Visible P/GW-body formation is disrupted
by depletion of components of the mRNA pathway, as Drosha, Dicer, Ago or GW182
[223][131][50]. This suggest a close connection between P/GW-bodies and the miRNA
pathway. However, only 1.3% of the cytoplasmic Ago pool resides in P/GW bodies [124]
and mRNA repression also occurs in absence of P/GW-bodies. This leads to the conclu-
sion that P/GW bodies are rather a consequence than a cause of sRNA-mediated gene
silencing [50].
Recent studies implicated a congregation of Ago and GW182 in endosomes and MVBs
[73] thus, linking miRNA-mediated gene silencing to endosomal trafficking [123]. Sup-
porting this, miRNAs have been found in exosomes [210]. However, the relation between
P/GW-bodies and MVB are not clear yet and further research is required to examine
the exact roles of distinct foci in the cell.
Supporting the nuclear function of Ago proteins, Ago-dependent RNAi effects were ob-
served in the nucleus in mammalian cells during the last years [177][99][100][9][110][100].
Moreover, Importin 8 was suggested as transport factor, targeting Ago proteins to the
nucleus [218].
Ago is not the only miRISC component that plays a role in the nucleus besides its cyto-
plasmic function. Till et al. found that human TNRC6B actively shuttles to the nucleus
[203]. By immunohistochemical analysis, TNRC6A was also observed in the nucleus
[229] and recently, it was even revealed that TNRC6A acts as a navigator for nuclear
import of Ago [155].
1.6 Post Translational Modifications
Besides the nature of the sRNA, the cellular localization and the miRNP composition,
post translational modifications (PTMs) are a factor further regulating the miRNP ac-
tivity. GW182 was shown to be phosphorylated in vivo [55], however, further research
is needed to elucidate the functional implications of GW182 PTMs.
Ago proteins comprise hydroxylation at proline P700, which is thought to support Ago
stability [173]. Ubiquitination plays a role to mark Ago for proteasomal degradation
[183]. Phosphorylation was first described by Zeng et al. who showed that phospho-
rylation of Ser S387 facilitates Ago2 localization to P-bodies [232]. Previously, it was
reported that phospohorylation of Ago2 Tyr Y529, which lies in the center of the MID
domain, affects sRNA binding [182].
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1.7 Mechanisms of Small RNA Functions
Based on their mode of action, subcellular localization and the nature of the sRNA
molecule, silencing pathways induced by sRNAs can be classified into different groups.
The major pathways are discussed in the following sections.
1.7.1 Posttranscriptional Silencing by SiRNA-mediated mRNA Cleavage
In RISC-mediated cleavage, a guide siRNA recruits Ago to a perfectly complementary
mRNA which is then cleaved. In humans, only Ago2 exerts slicing activity [130][145].
The minimal human RISC contains Ago2 bound to a ss siRNA [176]. Ago2 catalyses
hydrolysis of the phosphate backbone between the corresponding nucleotides 11 and 12 of
the guide strand [46] and release of a 5’ phosphate and a 3’ hydroxy terminus [191][142].
The cleaved target dissociates and is further degraded by the cellular decay machinery
[164][193].
1.7.2 MicroRNA-mediated Gene Regulation
MicroRNA-mediated Translational Repression and Decay
Recruiting the miRISC to specific mRNAs, miRNAs exert their function either on the
level of translational repression or mRNA destabilization.
Previous reports discussed several steps at which translation can be inhibited, which is
either initiation, elongation or termination [25]. Evidence that repression of translation
is exerted at the initiation step came from studies showing that miRNA-repressed target
mRNAs shift to lighter fractions in polysome gradients [9][171] and it was suggested that
miRNA pathway components prevent the eIF4E interaction to the 5’ cap [91]. Indica-
tions that repression occurs at the elongation step were provided by studies that detected
miRNA-repressed mRNAs in actively transcribing polysome fractions [141][163]. Finally,
some reports proposed that translation is inhibited by premature termination [169].
In the last years, it emerged that GW182 plays a key role in miRNA-mediated silencing.
GW182 was initially suggested to inhibit translational initiation by binding to PABP
and thus preventing PABP-eIF4G interaction and mRNA circularization [231][58]. It
was further indicated that the GW182-PABC interaction enhances deadenylation by
placing the poly(A) tail in close proximity to deadenylase complexes [58]. However, the
exact relevance of the GW182-PABP interaction is controversial and it is indicated that
PABP might additionally play a role independent of GW182 suggesting a more active
role for PABP in gene silencing [68][94].
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Figure 1.7.1: MiRNA-mediated translational repression and decay. One model proposes that
translational initiation is inhibited by interference of the miRISC with the eIF4F-cap interaction. Asso-
ciation of GW182 with PABP might prevent mRNA circularization leading to repression of translational
initiation. CCR4Not and PAN2/Pan3 mediate mRNA deadenylation, followed my cap removal through
the DCP1/DCP2 complex and final decay by XRN1 (adopted from [59]).
Recent studies revealed that mRNA degradation is a widespread effect of miRNA-
mediated repression [93]. MiRNA-mediated mRNA destabilization by decay mechanisms
involve the CCR4-Not and PAN2/PAN3 deadenylase complexes [28][57][17][37][17][57].
GW182 is not only a platform for deadenylases to gain access to the poly(A) tail but
also triggers DCP1/DCP2 mediated decapping and final mRNA decay by XRN1 [8].
Besides involvement of PABP and deadenylase complexes, EDD was implicated to be
essential for efficient miRNA-mediated repression in mouse embryonic stem cells through
direct interaction with GW182 [198]. Since EDD directly interacts with the decapping
activator RCK/p54 it was suggested to assist GW182 as additional module to recruit
miRNA effector proteins for translational repression [198][36][33].
As described above, miRNAs have a major impact on mRNA destabilization. However,
the relative contributions and exact sequential arrangements of the different effects have
not been elucidated [79]. Several studies revealed that miRNAs can repress their targets
in a two step mode. First, mRNA translation is inhibited followed by subsequent dead-
enylation, decapping and decay [59].
Posttranscriptional gene regulation is guided by miRNAs or RNA-binding proteins (RBPs)
through association with target sites in the 3’ UTR. TRIM-NHL proteins have been iden-
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tified as modulators of miRNA-mediated repression in mammals, flies and worms. The
interaction with Ago or other miRNA components can either result in enhanced or al-
leviated repression [82][189] [183][154][135]. The dead end homolog 1 protein (DND1)
prevents miRNA binding by association with the miRNA target site [107]. Similarly, the
Hu-antigen R protein (HuR) or the pumillo homology domain family member (PUF)
proteins target mRNAs to exert their regulatory functions [26][111][9]o[108][157].
Together, these studies show that a thorough knowledge of the interplay between the
miRNA machinery and RBPs is necessary to understand the mechanisms of miRNA-
mediated gene silencing.
MicroRNA-mediated Translational Activation
MiRNAs have been found to generally mediate posttranscriptional down regulation of
gene expression. However, more and more studies reveal that miRNAs can function
as translational activators depending on the RNA sequence, associated RNP factors or
cellular conditions [98]. In human cells, miRNAs were observed to oscillate between
repression and activation dependent on the stage of the cell cycle. Here, miR-369-3 di-
rects the association of Ago2 and FXR1, an RNA binding protein linked to the fragile
X syndrome, with the AU-rich element in the 3’ UTR of TNFα to stimulate translation.
Furthermore, they report that let-7 enhances translation during cell cycle arrest and
represses translation in proliferating cells [212]. Another study observed that miRNA-
10a interacts with the 5’ UTR of mRNAs encoding ribosomal proteins to stimulate
their translation during aa starvation [165]. Furthermore it was reported that the liver-
specific miRNA-122 enhances Hepatitis C virus (HCV) translation by targeting sites in
the 5’ UTR of the HCV genome [87]. These finding highlight the complexity of miRNA-
mediated gene regulation, in which the relevance of translational activation has to be
clarified.
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1.8 Aim of the Thesis
Ago proteins are embedded into miRNPs and constitute the central components of
miRNA-mediated gene silencing. They associate with GW182 proteins which have been
found to serve as a platform to recruit effector proteins triggering translational silencing
or mRNA decay.
To date, much progress has been made to reveal the functional relevance of the Ago-
GW182 interaction. However, there are many open questions especially about the un-
derlying binding mechanisms of both proteins:
Why does the GW182 sequence comprise numerous GW repeats? Do all GW-repeats
engage in Ago interaction? Is only one Ago protein involved or do several molecules
associate with GW182 in parallel? Is there a defined sequence motif with which GW182
binds to Ago? Why do some GW-repeats interact with Ago with high affinity whereas
others do not? Ago and Not1 both bind GW-repeats, are these repeats distinct motifs
and how is the specificity mediated? Where and how does GW182 bind Ago and does
GW182 associate with all four Ago proteins equally?
The aim of this thesis was to elucidate the molecular basis of Ago-GW182 interaction
addressing the above mentioned questions.
For this purpose, recombinant proteins first needed to be obtained to perform in vitro
studies. Therefore, a suitable expression and purification protocol had to be established.
Second, the recombinant proteins should be used in biochemical and biophysical ap-
proaches to map the binding sites and clarify the binding properties of Ago and GW182.
Finally, the data should be used to create a structural model displaying the Ago-GW182
interaction.
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2 Results
2.1 Definition of Working Constructs
In miRNA-mediated silencing, Ago proteins associate with a member of the GW182 pro-
tein family (in human TNRC6A, B, and C) in order to achieve efficient repression. To
extend our knowledge on the function of both proteins we aimed to better understand
the mechanism beyond their interaction. To perform in vitro studies, we established a
purification strategy to obtain members of both protein families in high purity.
2.1.1 TNRC6 Family Proteins
To get an overview of structural elements in TNRC6 proteins, a secondary structure
prediction using Quick2D [10] was performed for TNRC6B (see appendix). Except for
known domains (UBA 997-1055, Q-rich 1036-1218 and RRM 1535-1619) the protein is
predicted to offer very little structural content.
In a first attempt, full length proteins of TNRC6A, B and C were purified from insect
cells. All proteins were well expressed, soluble and could be enriched using a Nickel-
affinity column via their 6x His-tag (Figure 2.1.1). Nevertheless, the protein was not
stable upon further purification e.g. by ion exchange or size exclusion chromatography
(SEC). Similarly, shorter TNRC6B constructs covering the N-terminus (aa 1-1007) ex-
pressed in Escherchia coli (E. coli) or the carboxy C -terminus (917-1723) expressed in
insect cells did not yield stable protein (Figure 2.1.1). Alignment of TNRC6 family pro-
teins using MAFFT [105] (see appendix) identified two conserved regions (aa 599-683
and aa 861-911) in the N-terminal part of TNRC6B covering sites that were reported to
bind Ago in literature [54]. Both fragments were expressed in E. coli with an N-terminal
His-GST-tag and were purified to high homogeneity using affinity chromatography. For
some experiments, the His-GST-TNRC6B 599-683 preparation was further purified by
tag cleavage and SEC.
GST-tagged RRM domains of TNRC6A, B and C (Figure 2.1.1) as well as TNRC6A, B,
C full length, TNRC6B 599-683 and TNRC6B 861-911 were used to generate antibodies
against TNRC6A, B and C respectively, in collaboration with Dr. Elisabeth Kremmer.
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Figure 2.1.1: Purification of TNRC6 constructs. Proteins were purified as visualized by coomassie
stainingg after sodium dodecyl sulfate polyacrylamid gel electrophoresis (SDS-PAGE). TNRC6A, B, C
as well as TNRC6B constructs 1-999 and 917-1723 were prone to degradation, whereas the RRM domains
of TNRC6A, B, C and TNRC6B constructs 599-683 and 861-911 were stable.
Figure 2.1.2 gives an overview of constructs used and the success of expression, solubility
and purification.
Figure 2.1.2: Schematic of TNRC6 constructs. Schematic representation of the TNRC6 domain
organization and constructs used for purification attempts. Domains are color coded as follows: green:
GW-rich region, yellow: UBA domain, purple: Q-rich-region, dark gray: PAM2 motif, red: RRM
domain, linker region: gray. The success of expression, solubility and purification is indicated on the
right in green (good), yellow (medium) and red (failed) dots.
2.1.2 Argonaute Family Proteins
On the basis of secondary structure prediction carried out using Quick2D (see appendix),
several Ago2 constructs for expression in E. coli were designed.
All Ago2 fragments are listed in Figure 2.1.3. Expression was tested in several E. coli
strains using different solubility tags (His, His-GST, His-Sumo, His-Trx), lysis condi-
tions as well as co-expressing the interaction partner TNRC6B 599-681. Except for the
full length protein, all protein fragments were highly expressed. However, besides Ago2
449-575 none of them yielded soluble protein.
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Figure 2.1.3: Schematic of Ago2 constructs. Schematic representation of the Ago2 domain orga-
nization and constructs used for purification attempts. Domains are color coded as follows: N-terminal
domain: orange, PAZ: blue, MID: purple, PIWI: green, linker region: gray. The success of expression
and solubility is indicated on the right in green (good), yellow (medium) and red (failed) dots.
Therefore, Ago2 449-575, expressing the Ago2 MID domain, was tested for TNRC6B
599-681 interaction in a pulldown assay (Figure 2.1.4). Recombinant Ago2 449-575 was
mixed with GST-tagged TNRC6B 599-683 (lanes 2 and 3) and precipitated by glu-
tathione (GSH) beads. After washing, bound protein was eluted with GSH (lanes 5 and
6) and visualized by SDS-PAGE followed by coomassie staining. However, the Ago2
fragment was not sufficient to mediate the interaction.
In another attempt, the Ago protein from the archaeal species pyrococcus furiosus (pf)
was purified recombinantly and tested for interaction (Figure 2.1.3) as described for the
MID domain fragment. Here, even the pfAgo full length protein was not able to pull
down TNRC6B 599-683 (lanes 4 and 5).
Figure 2.1.4: The Ago2 MID domain and pfAgo full length protein are not sufficient to
bind TNRC6B 599-683. A) Ago2 499-575 and B) pfAgo can not be precipitated by TNRC6B 599-683
in a pull-down experiment (lanes 5, 6 and 4, 5 respectively).
21
2 Results
Since E. coli expression did not reveal an Ago construct that exhibited expression/ solu-
bility and TNRC6B binding capacity, we changed the expression system and established
the purification of human Ago full length proteins from insect cells according to the
Bac-to-Bac manual (Invitrogen). Ago1-4 were expressed and isolated by a three-step
purification, including Nickel-affinity chromatography, tag cleavage followed by a second
Nickel-affinity step and finally SEC. Due to a very low expression yield, only about 0.3
mg of pure protein were obtained from 1l culture of High Five insect cells (Figure 2.1.5
A).
We used recombinant full length Ago2 protein for analytical limited proteolysis (Fig-
ure 2.1.5 B) to find smaller interaction domains, that, after identification of their bound-
aries, could then be used for expression in E. coli. Samples were subjected to proteases of
different concentrations, incubated and separated by SDS-PAGE followed by coomassie
staining.
Figure 2.1.5: Purification and limited proteolysis of Ago. A) SDS-PAGE showing that Ago1-4
was purified to homogeneity. B) Ago2 was incubated with different concentration of several proteases
and the digestion products were resolved by SDS-PAGE.
However, Ago2 was highly stable in presence several proteases. Only after addition of
the protease subtilisin it was susceptible to degradation, even though no stable subfrag-
ments could be observed.
Taken together, we find that handling of TNRC6 full length protein or longer constructs
beyond purification by affinity chromatography is impractical, whereas domains (RRM)
or smaller constructs are highly stable. Strikingly, all four human Ago proteins are avail-
able in high purity. For the following experiments, we chose the full length protein of
Ago2 to study the interaction with TNRC6B.
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2.2 Identification of Argonaute 2 Interaction Motifs on
TNRC6B
It emerged from the literature that different GW-containing regions of TNRC6B are ca-
pable of Ago binding. However, a clear picture about the number of binding sites in the
TNRC6B sequence and their affinities to Ago2 did not arise. Here, we comprehensively
investigated the Ago2 TNRC6B interaction sites using a peptide array. The selected N-
terminal half of TNRC6B containing the GW-motifs required for Ago binding is (except
for the RRM) predicted to be unstructured. This is a good prerequisite for a successful
in vitro peptide scanning experiment in which short unstructured peptides are used.
Recombinant human Ago2 was isolated from insect cells and purified to high homogeneity
as described above (Figure 2.2.1 A). Figure 2.2.1 B schematically illustrates the setup of
the peptide array. 20-meric peptides overlapping in 15 aa and covering almost the com-
plete TNRC6B sequence were synthesized and spotted onto a nitrocellulose membrane
(Figure 2.2.1 C). The membrane was incubated with recombinant Ago2 and binding was
indirectly revealed by western blotting using a specific primary (anti-Ago2 11A9) [181]
and secondary (HRP- conjugated anti-rat IgG) antibody.
Figure 2.2.1: Experimental setup of peptide array. A) Domain organization of Ago2 and prepa-
ration of recombinant Ago2 used in the experiment. Domains are color coded as follows: N-terminal
domain: orange, PAZ: blue, MID: purple, PIWI: green, linker region: gray. B) Schematic illustration
of the peptide array setup used to identify Ago2 interaction sites on TNRC6B. C) Domain organization
of TNRC6B. Domains are color coded as follows: green: GW-rich region, yellow: UBA domain, purple:
Q-rich-region, dark gray: PAM2 motif, red: RRM domain, linker region: gray. The regions that were
covered by peptides are indicated as A-I and J-M.
The membrane incubated with Ago2 shows distinct regions within the TNRC6B N-
terminal as well as the C-terminal fragment that are capable of Ago2 binding (Fig-
ure 2.2.2 A and B). Intensities of peptides A-I that offered binding were quantified using
the software ImageJ and normalized to peptide E11, that was binding the strongest
(Figure 2.2.2 C).
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We find three hotspots that strongly interact with Ago2 (Figure 2.2.3 black circles), as
well as several sites with medium (grey circles), weaker (light grey circles) and faint
(white circles, not included in quantification) binding. Of note, all peptides that bind
Ago2 share the presence of at least one Trp in the sequence. Surprisingly, not all peptides
that bind with high affinity to Ago2 require a Gly flanking the Trp, as seen for peptide
D3 containing an SWD and SWN motif.
In the control experiment, in which Ago2 has been omitted from the reaction, primary
and secondary antibodies used for immuno-detection of bound Ago2 showed almost no
unspecific binding besides the spots L9-12 and M3 (Figure 2.2.2 B).
Figure 2.2.2: Peptide array identifies distinct Ago2 binding sites on TNRC6B. Several
TNRC6B peptides allow Ago2 binding. 20-meric TNRC6B peptides of A) regions A-I and B) regions
J-M with an offset of 5 aa were covalently coupled to a nitrocellulose membrane, incubated with recom-
binant Ago2 followed by specific Ago2 detection with the 11A9 antibody [181]. Upper panel: Control
experiment carried out lacking Ago2 incubation step. Lower panel: Incubation with Ago2 before moni-
toring TNRC6B binding. C) Signals in the peptide array A) were quantified using the ImageJ software
(http://rsb.info.nih.gov/ij/), showing different levels of affinity. D) Alignment of the peptide used for
11A9 antibody generation and peptides of TNRC6B sequence unspecifically binding the 11A9 antibody
in the control experiment displays a consensus sequence highlighted in blue.
Interestingly, alignment of those peptides with the peptide used for generation of the
anti-Ago2 antibody 11A9 [181] reveals a conserved sequence motif consisting of the
aa sequence (A/V)GPAL within peptides 11A9 and L9-12 (Figure 2.2.2 D). M3 only
partially covers the complete sequence explaining the weaker binding. From the 15-
meric peptide this short 5 aa stretch is most likely the epitope necessary and sufficient
to be recognized by the 11A9 antibody.
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Figure 2.2.3: List of TNRC6B peptides spotted on the membrane with their Ago2 affinity
indicated. Set of TNRC6B peptides used in the peptide array. The Ago2 binding strength is illustrated
by black (strong binding), grey (medium binding), light grey (weaker binding), white (faint binding)
and dashed white (no binding) dots. Trps are highlighted in blue.
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In conclusion, we find sites in the N-terminal region of TNRC6B that specifically interact
with Ago2. Interestingly, not all Trps engage in Ago binding and Gly flanking the Trp
appear not to be a requirement for efficient binding.
2.3 Analysis of Tryptophan Flanking Amino Acids
Our peptide scan revealed that not all peptides containing Trps which might be suitable
for Ago2 binding, interact with Ago2. Therefore, we performed a second peptide array
to further elucidate Ago2 binding requirements (Figure 2.3.1).
For this, we set up a mutational screen based on peptide E11, that had one of the
strongest interactions with Ago2. Several peptides were designed and analyzed by pep-
tide array probing using Ago2 and immuno-detection with 11A9 antibody (Figure 2.3.1).
To exclude artifacts of the signal strength e.g. by unequal washing or antibody binding,
several wild type (wt) peptides were spread over the membrane to ensure comparable
results (Figure 2.3.1 A: A1; D: C16, D5; E: E14; F: F5)
Alanine Scan of Peptide E11
To test the requirements for aa flanking the Trp, we first performed an alanine (Ala)
scan by substituting each aa of the peptide sequence flanking the Trp to the left with Ala
(Figure 2.3.1 A: A2-A12). Here, no influence on Ago2 binding was observed, whereas
introducing an Ala at the position of the Trp (A13) completely abolished binding. Sub-
stitution of aa flanking the Trp to the right (A14-B1) did not have a significant impact
on Ago2 binding in comparison to wt (C16). This suggests, that a single aa does not
have an impact on Ago2 binding, however, the presence of a Trp is strictly required.
Multiple Alanine Substitutions in Peptide E11
The Ala scan showed that substitution of a single aa does not influence binding to Ago2.
Next, we aimed to find out if substitution of multiple aa shows an effect. Thus, we
systematically replaced all aa N-terminal to the Trp by Ala (Figure 2.3.1 B: B2-B11).
This did not lower binding, whereas substitution of C-terminal aa decreased the affinity
(B12-B17).
Replacing the entire peptide except for the central Trp or Gly/Trp/Gly by Ala (B18-C1)
had an even stronger effect. Here, binding was reduced indicating that the composition of
the Trp flanking aa is indeed important for efficient binding. Similar to A13, insertion of
Ala at the positions of the central Gly/Trp/Gly tripeptid completely abolished binding,
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whereas substitution of only the Trp flanking Glys by Ala did not affect binding (C2,
C3). This confirms the key role of the Trp.
Figure 2.3.1: Peptide array for mutational analysis of peptide E11. Peptide array showing
different effects of aa substitutions in peptide E11 (Figure 2.2.3). Upper panel: Control experiment car-
ried out lacking Ago2 incubation step. Lower panel: Incubation with Ago2 before monitoring TNRC6B
binding. List of designed peptides with the type of mutation indicated above and highlighted in gray.
Trps are highlighted in blue. A) Ala scan of peptide E11. B) Multiple Ala substitutions in peptide
E11. C) Role of single aa and Trp position. D) Role of single aa and Trp position. E) Impact of aa
neighboring the Trp. F) Ago2 binding efficiency of Not1 binding sites and the prion protein.
Role of Single Amino Acids and the Tryptophan Position
Substitution of multiple aa indicated that the overall aa composition indeed plays a role
in Ago2 binding. We thus chose a polyGly peptide and tested whether the insertion
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of single aa occurring at its position in peptide E11 might contribute to binding and
enhances the affinity to Ago2 (Figure 2.3.1 C: C5-13).
Similar to the polyAla peptide (C1), a polyGly peptide containing one Trp showed
reduced affinity (C5). Based on that, we inserted valine (Val) (C6), leucine (Leu) (C7),
Ser (C8), Asn (C9), threonine (Thr) (C10), glutamine (Gln) (C11), isoleucine (Ile) (C12)
and lysine (Lys) (C13), however, none of them increased the affinity, suggesting that
single aa do not determine the binding properties.
Unexpectedly, changing the position of the GWG tripeptide to the very N- and C-
term (Figure 2.3.1 C: C14-15), respectively, did not lower the affinity compared to the
wt (C16), leading to the conclusion that also the position of the key Trps within the
peptide is not a crucial factor.
Tryptophan Requirements
Having proven that the Trp is a key requirement for efficient binding in the peptide
sequence, we next characterized its role by replacing it with aa featuring related charac-
teristics of Trp (Figure 2.3.1 D: D1-D4).
To test whether the aromatic ring is necessary for binding, we replaced the Trp by the
aromatic residues Phe and Tyr, respectively (D1-2). Faint binding was found for the
the Phe peptide, whereas the Tyr peptide completely lost its affinity. This is consistent
with a previous report [188] where the authors found phenol from the crystallization
condition bound to the protein.
Peptide D3 and D4 were used to check whether the hydrophobic (Leu) or bulky (arginine
(Arg)) property of the Trp are sufficient to facilitate binding. This is not the case, since
the interaction was completely lost.
In Figure 2.3.1 D: D5-D10, peptides from the first peptide array (Figure 2.2.2), that
were later used for further experiments, were again spotted.
Impact of Amino Acids Neighboring the Tryptophan
Finally, we screened for possible neighboring aa of the Trp. Changing a Asn/Trp/Gly
tripeptide (D10) to a Gly/Trp/Gly tripeptide (D11) does not have an effect. Next, we
replaced the directly flanking aa by a set of aa that is also abundant in the TNRC6B
sequence (Figure 2.3.1 E: D11-E13). Here, for all variations the interaction remained at
wt level, suggesting that a Gly/Trp Trp/Gly dipeptid is preferred but not an absolute
requirement for efficient binding.
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Argonaute 2 Binding Efficiency of Not1 Binding Sites and the Prion Protein
Recent publications revealed binding sites for Not1 on GW182 [57][28]. The correspond-
ing TNRC6B peptides (Figure 2.3.1 F: E15, E19, F1, F2) and mutations (E16, E17,
E18, E20) were tested in a peptide array for Ago2 binding in comparison to peptide E11
(F5). For peptides E15-E20 the so-called "ring spot effect" was noticed, caused by too
tight peptide density. Consequently, the binding can only be assessed qualitatively. In
comparison to peptide E11 (F5), peptide F1 shows diminished binding, whereas binding
of peptide F2 to Ago2 seems to be equivalent to E11.
Recently, it was published that the Gly/Trp/Gly containing prion protein is able to bind
Ago, thereby promoting accumulation of miRNA effector complexes [72]. Thus, a pep-
tide stretch derived from the prion protein sequence containing one or two Gly/Trp/Gly,
respectively, was compared with peptide E11 (Figure 2.3.1 F: F3, F4), which had the
strongest affinity in the first peptide array. Notably, only very faint binding was ob-
served. The additional Gly/Trp/Gly (F4) enhanced the affinity to Ago2. Thus, Not1
and the prion protein can bind Ago2, however, with weaker affinity than peptide E11
derived from the TNRCB sequence.
In summary, we found that a single aa within the TNRC6B peptide does not have influ-
ence on Ago2 binding. Rather the overall aa composition seems to be the determining
factor with the aromatic ring of Trp mainly engaged in binding .
2.4 Tryptophan - Argonaute 2 Contacts on an Atomic Level
Based on the findings we gained from the peptide arrays, which showed that one Trp was
sufficient for binding, we further investigated the binding of TNRC6B to Ago2 in molec-
ular detail. We analyzed the interaction on an atomic scale using saturation transfer
difference (STD)-NMR. STD-NMR allows to measure transient binding of small ligands
to larger protein receptors and detection of the ligand parts involved in binding.
One advantage of this technique is that only small quantities of unlabeled protein are
needed. This method is ideal for studying large proteins, that are difficult to express
and are therefore not available in larger quantities.
The principle underlying this approach is illustrated in Figure 2.4.1 A. Protons of a large
receptor protein (Ago2) are selectively saturated for a defined period of time (saturation
time) by irradiation of spectral regions containing "wings" of broad resonances (in this
experiment -1 ppm). Those "wings" are, due to the structured nature of proteins, specific
for macromolecules and do not occur in small ligands like peptides. Rapid intramolec-
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ular propagation of the saturation by spin diffusion results in transfer of saturation to
the bound ligand (here the TNRC6B peptide) if protons are in close proximity (< 5 Å)
to Ago2 protons.
This saturation leads to bleaching of the corresponding signals in the NMR spectrum.
Finally, a comparison of a saturated and unsaturated NMR spectrum allows the identi-
fication of the binding area after assignment of protons in the peptide sequence.
Six peptides with different affinities were chosen from the peptide array for STD-NMR
measurements (Figure 2.2.3 C12, D3, E11, F9, F16, G). STD-NMR spectra were recorded
as exemplarily represented for peptide E11. Figure 2.4.1 B shows a section of a typi-
cal one dimensional (1D) -proton (1H) -NMR spectrum. Chemical shifts of protons are
plotted on the x-axis. For proteins, they are typically in the range of 0-10 ppm and rely
on the molecular structure, solvent, temperature, neighboring groups and the magnetic
field in which the spectrum was recorded. Using statistics (www.bmrb.wisc.edu), the
chemical shift of each proton in an aa can be assigned to a certain region in the NMR
spectrum. The y-axis displays the relative intensity of each signal.
Figure 2.4.1: Schematic illustration of STD-NMR experiment applied to the protein recep-
tor (Ago2) and ligand (peptide) complex. A) Selective saturation of receptor signals is transferred
to the peptide protons by spin diffusion. The stronger the receptor ligand contact between two pro-
tons, the stronger is the STD effect. B) The set-up involves recording three 1D-1H-NMR spectra. A
standard 1D-1H-NMR spectrum as a reference (green), a difference spectrum of the reference spectrum
and a 1D-1H-NMR spectrum with selective saturation of the receptor named STD-spectrum (blue) and
a difference spectrum without addition of Ago2 as control (red). The difference spectrum only shows
signals corresponding to bound ligand protons. Indicated are chemical shift regions corresponding to
the respective protons.
First, a 1D-1H-NMR reference spectrum of the TNRC6B peptide was recorded (green).
As described above, each peak corresponds to a proton of an aa in the peptide. Protons
of amides can be observed at around 8 ppm, protons of aromatic rings as well as amine
protons at around 6.5-7.5 ppm, Hα proton appear in a range of 3-4.5 ppm, whereas the
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region between 0-1 ppm is typical for methyl protons.
In the following, the difference between the reference and the saturated spectrum will be
called STD-spectrum. In this spectrum (blue), only protons of the E11 peptide bound
to Ago2 are visible as clarified above. Comparison of this spectrum with the reference
spectrum reveals that the STD-spectrum lacks some peaks e.g. in the areas from 8-9 ppm
or 2-4 ppm. This loss of signals is due to protons that were not bleached by saturation
transfer and thus, do not interact with Ago2.
The control spectrum (red) was recorded with the same conditions as the STD-spectrum
without adding Ago2. Peaks appearing here, are due to unspecific irradiation of the
ligand and are subtracted from the STD-spectrum (corrected STD-spectrum). Since
Ago2 was specifically irradiated at -1 ppm, hydrophobic residues that contain methyl
protons, which have a chemical shifts close to the irradiation frequency of about 0-1 ppm
(see Figure 2.4.1 B), are most likely affected by unspecific irradiation in comparison to
those of the indole ring (7-7.5 ppm).
Analysis of the spectrum shown in Figure 2.4.1 B leads to two observations: First, most
likely the peaks appearing at 7-7.5 ppm are resulting from the Trp typically expected in
this region. Second, there is no peak in the chemical shift range of Gly (3.8-4.2 ppm).
This leads to the assumption that the Trp is strongly involved in binding whereas its
directly neighboring aa Gly completely lacks binding. To better assess the absolute
magnitude of the STD effect Mayer and Meyer [144] introduced the STD amplification
factor described by the following equation:
In this equation, I0 represents the reference spectrum and I0-Isat describes the intensity
of the corrected STD spectrum, normalized with a concentration dependent factor (lig-
and excess) (Figure 2.4.1 B).
TNRC6B peptides that were proven to interact with Ago2 in the peptide array (Fig-
ure 2.2.2) were chosen for STD-NMR analysis. Prior to the actual STD-NMR mea-
surements, backbone assignment of the aa in the TNRC6B peptide sequence was per-
formed using two dimensional total correlation spectroscopy (2D-TOCSY) and natural
abundance 13C-heteronuclear single quantum coherence (HSQC) measurements. In 2D-
NMR, two frequency axes, representing chemical shifts, are used to enhance resolution
and thus, providing more information. In the TOCSY experiment, cross peaks of cou-
pled protons are detected which give characteristic signal patterns for each aa, allowing
to assign the peaks to aa in the peptide sequence. Assignment is further facilitated by
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combining the information provided by 2D-TOCSY with 13C-HSQC. Here, correlations
between nuclei of two different types, in our case 1H and the naturally abundant 13C,
that are separated by one bond are observed. The resulting patterns are characteristic
for the proteins structural integrity as they depend on the chemical environment of each
atom; therefore the HSQC spectrum can be considered as a fingerprint of the protein.
After assignment of signals to the corresponding aa, STD-NMR spectra were recorded
as exemplarily described above. Integrals of the peaks with a width of 0.3 ppm were
obtained and used for calculation of the STD amplification factor, as described above.
The diagrams in Figure 2.4.2 display the STD amplification factors. Plotting the STD
amplification factor against the saturation time results in a curve reaching a plateau.
This plateau is due to TNRC6B peptides dissociating from Ago2 and emitting their
saturation before recording the NMR spectrum, if the period of saturation time is too
long.
In each diagram, one aa is represented by the same color (e.g. blue for Trps). Each
proton of the respective aa side chain is displayed as a symbol (e.g. triangle for a Hζ2
proton).
As expected, a plateau is reached after a certain saturation time, for most protons in
the range of 4-8 s. For all tested peptides, protons of the Trp indole ring (blue) show
the strongest binding.
Inspection of their STD amplification factors shows that similar intensities were obtained
for peptide C12 and E11 (between 3-14) as well as for peptides F16 and G2 (between 1-
8), whereas D3 reaches much higher values (up to 25) and F9 much lower values (0-1.5).
The difference of binding affinity in the peptide array and the values of the STD ampli-
fication factors in comparison to the different peptides is reasonable since proximity and
binding strength do not directly correlate with each other.
Peptides D3, G2 and F16 contain two Trps in the sequence that can both be designated
in the spectrum. Figure 2.4.2 F shows two curves for the Hδ1 as well as for the Hη2
proton originating from different Trps. Thus, both Trp bind Ago2, although from this
data it cannot be clarified whether they bind at the same time or successively. Less
significantly, several other aa were in close proximity to Ago2, possessing weak signals.
Of note, the Trp neighboring Gly do not bind at all.
The relative STD of each proton in the Trp is illustrated on the right side of the graphs.
Here, the proton with highest STD amplification factor (Hη2 highlighted in red) was set
to 100%. On the basis of this, values for the other protons were calculated.
Strikingly, for most of the measured peptides, protons Hη2 and Hζ2 of the Trp offer the
highest relative STD leading to the assumption that those protons must be most deeply
buried into a pocket on Ago2.
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Figure 2.4.2: STD amplification factors of measured peptides Left panels: Time course of STD
amplification factors plotted against the saturation transfer time calculated for several peptides from
peptide array (Figure 2.2.2), A: D3, B: E11, C: G2, D: C12, E: F9, F: F16. Different amino acids are
highlighted by colors, while different symbols are used for protons observed. Right panels: Structure of
tryptophane with proton names annotated. The value of the proton with the highest STD amplification
factor was set to 100% and is highlighted in red and relative values are then indicated for the other
protons, accordingly. STD-NMR measurements were recorded by Dr. Janosch Hennig from the lab of
Prof. Michael Sattler.
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With this knowledge, results from the second peptide array (Figure 2.3.1) are explainable.
The major interaction is mediated by the benzole part of the indole ring. The benzole
ring is also available in a Phe, although its lacking the pyrrole what is most likely
decreasing the affinity. In the Tyr molecule a hydroxy group is sitting at the position of
the Hη2 proton, hindering the molecule to properly bind into the pocket.
Taken together, we found that mainly the Trp is binding and that this binding is mainly
mediated by Hη2 and Hζ2 protons. Weak signals of the remaining aa might be due
to supporting affinity, the spatial proximity to Ago2 by flanking the Trp, or unspecific
irradiation.
2.5 A Tryptophan-containing TNRC6B Fragment that
Binds Argonaute 2 is Unstructured in Solution
STD-NMR experiments elucidated that all TNRC6B peptides bind to Ago2 through
their Trps. In case two Trps are present both are involved in binding (Figure 2.4.2
A, C, F). Thus, we were wondering how the binding is facilitated in the context of a
larger fragment. To test this, we chose a 83 aa long TNRC6B construct ranging from aa
599-683. This region covers peptides E8-F2 (Figure 2.2.3) including peptide E11, which
binds Ago2 efficiently in our peptide array experiments. In order to identify important
residues for function and folding, we analyzed cross species conservation of this region. In
contrast to most of the N-terminal GW regions, this section is conserved (see appendix)
(Figure 2.5.1).
Figure 2.5.1: Multiple sequence alignment of TNRC6B 599-683 orthologs. TNRC6B orthologs
from selected organisms were aligned with MAFFT [105] using the Jalview software [216]. Conserved
sequence motifs are shaded in blue. Predicted secondary structure elements are displayed above the
sequence.
The Gly/Trp/Gly (GWG 29-31 corresponding to TNRC6B aa 622-624) tripeptide of E11
is conserved in vertebrates and insects, as well as some flanking aa, such as S26 (S619)
and Q37 (Q630). However, most of the other Trps (W41, W60, W87 corresponding to
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TNRC6B W634, W653, W680) are also conserved. Secondary structure analysis only
identifies local secondary structure elements whereas the overall structure is predicted
to be disordered (Figure 2.5.1).
To find out whether TNRC6B 599-683 exhibits local secondary structure elements that
might contribute to binding in vitro, the secondary structure of recombinant TNRC6B
599-683 (Figure 2.1.1) was assessed by circular dichroism (CD) spectroscopy (Figure 2.5.2
A). The experimental folding analysis reveals a random-coil-like spectrum with no signif-
icant structural content. Unlikely, but local structural elements that could be important
for binding can not be fully excluded.
We then recorded relaxation experiments of the construct to investigate protein back-
bone dynamics (Figure 2.5.2 B). Relaxation describes the process by which spins return
to their equilibrium state after excitation. The return back to equilibrium is described by
two constants, T1 and T2. T1 is the longitudinal relaxation time describing the return
of the magnetization in z-direction while T2 describes the vanishing of magnetization
in the xy-plane. These two constants can be directly related to the protein dynamics.
While slower global movements are reflected in the T1 value, fast local motions on the
ns time scale are affecting the T2 relaxation.
Figure 2.5.2: CD spectrum, 15N NMR relaxation data and heteronuclear NOE of TNRC6B
599-683. A) CD spectrum of TNRC6B 599-683 reveals a random-coil-like structure. B) Average
relaxation times are 0.6 s (T1) and 0.25 s (T2), the average value for heteronuclear NOE is about 0.4
as indicated with a gray line. A flexible stretch with enhanced T1, T2 relaxation time and reduced
heteronuclear NOE is marked in red. From T1 and T2 the rotational correlation time was estimated to
be t=2.9 ns. NMR measurements were performed by Dr. Janosch Hennig.
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For backbone assignment of TNRC6B 599-683, the protein was 15N13C-labeled during
expression using M9 minimal medium. Purification was performed in three steps using
GST-affinity chromatography, tag-cleavage and SEC. Backbone resonances were assigned
using standard triple resonance techniques as HNCA, CBCACONH and HNCACB [187].
The correlation time describing the molecular tumbling in solution estimated from T1
and T2 is t=2.9 ns. This is lower than the correlation time expected for a globular 10
kDa protein (t=5-6 ns), due to the unfolded nature of the protein.
Data gained from this measurements are interpreted on a residue-by-residue basis. The
protein shows no internal dynamics except for the termini and a stretch (LQTLLS) in the
N-terminal part which showed elevated relaxation rates meaning more flexibility. Thus,
this stretch might have a special role in folding or function of the protein. Together, also
the NMR relaxation experiments suggest an unfolded TNRC6B fragment
To solidify our findings, backbone heteronuclear NOE rates of TNRC6B 599-683 were
measured, which identify motions of N-H bonds. Decreased values occur if an individual
motion is faster than the overall tumbling, whereas negative values imply the occurrence
of very fast large motions, which are very frequent in unfolded proteins. For a folded
protein values between 0.5 and 0.8 would be expected. Our measurements demonstrate
a rather flexible unstructured protein with values of about 0.5. Consistently, the area
found to have different dynamics in T1 and T2 relaxation has even greater flexibility
with values below zero.
Figure 2.5.3: Secondary chemical shifts calculated for TNRC6B 599-683. Secondary structure
analysis based on the 13C secondary chemical shifts of the free TNRC6B 599-683 fragment indicating
the absence of significant population of secondary structure. NMR measurements were performed by
Dr. Janosch Hennig.
Further, secondary structure prediction based on the difference of measured Cα and Cβ
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chemical shifts to random coil chemical shifts of the same nuclei (Figure 2.5.3) [192][221]
confirms the results found before. Values of all residues are below ±6 ppm, statistically
indicating that no secondary structure is present. Taken together, all our measurements
imply that TNRC6B 599-683 is a highly flexible protein with no preformed defined folds
or structural elements that might contribute to the Trp recognition by Ago2.
2.6 TNRC6B Fragment Binds to Argonaute 2 with a low
Micromolar Affinity
As NMR and CD analysis helped to reveal the structural properties of TNRC6B 599-683
itself, we next addressed the binding affinity of TNRC6B 599-683 to Ago2. First, we
tested which proteins of HeLa lysate are able to bind to TNRC6B 599-683 in a bio-
chemical pulldown assay (Figure 2.6.1). Therefore, GST-tagged TNRC6B 599-683 was
coupled to GSH beads and incubated with HeLa whole cell lysate followed by elution
with GSH. The pulldown quality was ensured by SDS-PAGE and visualized by silver
staining. A gel slice containing proteins precipitated by GST-TNRC6B 599-683 was cut
out as depicted in figure 2.6.1 and analyzed by mass spectrometry (MS). All four human
Figure 2.6.1: Pulldown of proteins from
HeLa lysate by TNRC6B 599-683. Whole
cell HeLa lysate was incubated with GST-
tagged TNRC6B 599-683 followed by GST-
pulldown. Precipitated proteins were analyzed
by SDS-PAGE and visualized by silver stain-
ing. 5% input samples (lanes 2 and 3) and 30%
eluates (lanes 5 and 6) were loaded. The gel
was cut above the 50 kDa marker band and
proteins were identified by MS. The ratio of
pulled down Ago fractions are indicated on the
right.
Ago proteins were identified by MS. The distribution of bound Ago1-4 was determined
from the peptide intensities to 26% Ago1, 61% Ago2, 12% Ago3 and less than 1% Ago4.
This is in agreement with a previous report [170], where the authors found 20-25% Ago1,
60% Ago2, 15% Ago3 and about 1% Ago4 of the total Ago protein pool in HEK 293T
or HeLa S3 cells. Thus, there is no preference of TNRC6B 599-683 to one of the Ago
proteins.
Table 2.6.1 lists all proteins that were pulled down from HeLa lysate with at least five
identified peptides.
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Table 2.6.1: Table of proteins pulled down together with TNRC6B 599-683 from HeLa
lysate Several proteins were precipitated by GST-tagged TNRC6B from HeLa lysate and identified by
MS. Bound proteins are listed with their protein names, gene names, Uniprot ID, Peptide count and
Intensity.
We demonstrated that a recombinant TNRC6B fragment is suitable to pull down en-
dogenous Ago protein. Next, we tested whether the same fragment also binds recombi-
nantly expressed Ago2 and proved the interaction by an biochemical in vitro pulldown
assay (Figure 2.6.2 A). Recombinant proteins were mixed and then incubated with GSH
beads. After elution with GSH, samples were analyzed by SDS-PAGE and visualized by
coomassie staining. In comparison to the control sample (lane 6), recombinant Ago2 is
clearly precipitated by TNRC6B 599-683 (lane 5).
In summary, TNRCB 599-683 not only efficiently binds endogenous Ago2 but also the
recombinant protein. Based on that, we designed in vitro experiments using recombinant
proteins to further characterize the interaction.
To assess whether the proteins oligomerize or aggregate upon binding dynamic light
scattering (DLS) was conducted (Figure 2.6.2 B). Small molecules are constantly mov-
ing in solution due to their Brownian motion. Recording this diffusion by analyzing the
intensity of scattered light using the autocorrelation function allows to determine the
hydrodynamic radius (RH) of proteins as a parameter of its size.
Before the measurement, recombinant proteins were filtered and centrifuged to remove
aggregates. DLS shows that TNRC6B 599-683 and Ago2 measured alone are monodis-
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perse and have a hydrodynamic radius of 1.34 nm and 3.05 nm, respectively. After
mixing both proteins, two peaks corresponding to a RH of 1.17 nm and 3.76 nm are
apparent. No high molecular weight peaks are found. Thus, Ago2 and TNRC6B do not
aggregate upon binding under our experimental conditions.
Figure 2.6.2: TNRC6B 599-683 directly interacts with Ago2 and the complex does not
aggregate upon binding. A) Ago2 can be efficiently precipitated by TNRC6B 599-683 in a GST-
pulldown assay. Recombinant proteins were mixed, bound protein precipitated using GSH beads and
analyzed by SDS-PAGE followed by coomassie staining. 5% input samples (lanes 2 and 3) and 30%
eluates (lanes 5 and 6) were loaded. B) DLS data shows small particles for TNRC6B 599-683 and Ago2
alone (RH=1.34 nm and 3.05, respectively) as well as for the complex (RH= 1.17 nm and 3.78 nm).
Intensities were normalized for molecular weight as indicated by a red mark.
Following DLS, we established a biophysical assay based on fluorescence polarization
(FP) spectroscopy to measure the affinity of the TNRC6B Ago2 interaction. Polariza-
tion of fluorescent light depends on the motion and thus, size of the analyzed molecule.
TNRC6B was labeled with a fluorescence dye at a Cys in the very N-terminus of the se-
quence and mixed with recombinant Ago2 at increasing concentrations. Equilibrium dis-
sociation constants (KD) of 1.1±0.2 µM and 1.9±0.5 µM for the interaction of TNRC6B
599-683 and Ago2 were acquired in two independent measurements (Figure 2.6.3). A
KD in the low µM range is reasonable assuming an involvement of only a few aa.
Together, TNRC6B 599-683 efficiently associates with endogenous Ago1-4 and recombi-
nant Ago2 with an affinity determined in vitro in the low µM range.
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Figure 2.6.3: FP measurement of TNRC6B 599-683:Ago2 interaction. In FP measurements,
the KD of TNRC6B 599-683:Ago2 interaction was A) 1.1±0.2 µM and B) 1.9±0.5 µM, respectively
(mean and deviation were calculated from a triple measurement for each sample).
2.7 Tryptophan Flanking Amino Acids Contribute to
Binding
Previous experiments (Figure 2.3.1, Figure 2.4.2) indicated that aa flanking the Trp
might contribute to binding. To examine this in molecular detail, we performed NMR
titration experiments using 15N-HSQC measurements.
Here, the correlation in the protein backbone amides between 15N and 1H is recorded.
The resulting spectrum displays one dimension for the 1H nucleus and one dimension
for the 15N nucleus, with one peak for each 1H attached to a 15N. For this, 15N was
incorporated into the TNRC6B 599-683 protein during expression using M9 medium.
Purification was performed using a GST-affinity step, followed by tag cleavage and SEC.
A series of 15N-HSQC spectra was recorded at increasing Ago2:TNRC6B 599-683 ratios.
Ideally, a concentration dependent movement of single aa peaks, termed chemical shift
perturbation (CSP), is observed, resulting from a change of the chemical environment in
case direct interaction occurs. On the other hand, the intensity of the peak can decrease
upon environmental change due to line broadening. Both factors are used to map the
interaction site of Ago2 on TNRC6B 599-683.
Figure 2.7.1 A shows a superposition of the 15N-HSQC reference spectrum of free
TNRC6B 599-683 (blue) and the bound form in the presence of Ago2 (red) in a mo-
lar ratio of 1:1. With increasing Ago2 concentrations a set of signals decreases in its
intensity levels, e.g. signal corresponding to aa L15, T18 or T28. Few resonances un-
dergo a chemical shift, like aa D21, R23 or V40. Some resonances demonstrate both
signs of direct interaction.
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Figure 2.7.1: NMR titration experiments of TNRC6B 599-683 and Ago2. A) Overlay of
1H15N-HSQC spectra of TNRC6B 599-683 alone (blue) and after addition of 1:1 ration of Ago2 (red).
aa corresponding to the peaks are indicated. B) NMR titration experiments were used to calculate
the peak intensity ratios of a 0.1:1 (gray) and 1:1 (black) TNRC6B 599-683:Ago2 compared to the free
TNRC6B 599-683 reference spectrum. Reduced intensity is observed for T13-W41 (TNRC6B 606-634).
C) CSP correspond to the region with reduced affinity. aa colored in gray could not be assigned. NMR
titration experiments were performed by Dr. Janosch Hennig.
For analysis, peak intensities of free TNRC6B 599-683 (blue spectrum) and after addition
of Ago2 (red spectrum) were calculated and set in relation to display the differences. Ra-
tios of peak intensities were plotted for each residue after addition of molar ratios of 1:0.1
TNRC6B 599-683:Ago2 (gray) and 1:1 TNRC6B 599-683:Ago2 (black) (Figure 2.7.1 B).
If no interaction occurs, peak intensity ratios of free TNRC6B 599-683 and the sample
containing Ago2 are supposed to be 1 (Figure 2.7.1 B gray bars), since environmental
conditions should theoretically be constant. However, higher protein concentrations in
the sample also influence the ligand even without binding. In our experiment, the base-
line shows a general decrease in intensity upon addition of higher protein concentrations
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(1:1 TNRC6B 599-683:Ago2) down to 0.8 (Figure 2.7.1 B black bars). For CSP analysis,
distances of the same peaks in the blue and red spectrum were calculated (Figure 2.7.1
B).
Residues highlighted in gray in the sequence below the plots could not be assigned, thus
no conclusion about the binding can be drawn from that. A reason for this might be that
it is not possible to distinguish between resonances exactly lying on top of each other.
Here, this is the case for three out of five Trps and their C-terminally flanking Gly. Since
all Trp are part of a GWG tripeptide the very similar environment, in contrast to the
Trp lying within a TWD or GWE, leads to the same chemical shift. A possible reduction
in intensity and thus interaction to Ago2 can only be assessed from neighboring residues.
Intensities of residues T13-T28 (TNRC6B 606-621) are strongly reduced, also the region
from Q32-W41 (TNRC6B 625-634) is diminished, covering the Trps W30 (TNRC6B
W623) and W41 (TNRC6B W634). Chemical shift perturbations are rather weak but
cover the same region as we see for the intensity decrease. This is in accordance with
the data we have obtained in the peptide array.
In summary, we observed that the N-terminal region comprising residues T606- W634
ofTNRC6B 599-683 clearly interacts with Ago2.
2.8 Two Proximal Tryptophans are Necessary for Effective
Binding
In NMR titration experiments we identified a region covering only two out of five possible
Trps that contribute to Ago2 binding. We used GST-pulldown assays to further define
the role of all Trps. Mutations were introduced into TNRC6B 599-689, substituting five
Trps in the TNRC6B fragment with Ala in different combinations in order to investigate
their role in complex formation. Mutants were expressed and purified as described for
the wt protein (Figure 2.1.1). GST-tagged TNRC6B 599-683 and the mutants were in-
cubated with recombinant Ago2 and immobilized on GSH beads. After washing, bound
protein was analyzed by SDS-PAGE followed by coomassie staining (Figure 2.8.1).
Individual mutation of W623 or W634 completely abolished Ago2 binding (lower panel:
lanes 3 and 4), whereas the mutation of W653, W666 or W680 did not affect binding
at all (lower panel: lanes 5, 6 and 7). This is consistent with the NMR data suggesting
impact on exactly those residues upon titration of Ago2. Intriguingly, the presence of
only one Trp, with all other Trps substituted by Ala, is not sufficient for binding (lower
panel: lanes 3 and 4). Having observed this, we designed constructs offering both W623
and W634 (lower panel: lane 17) as well as W653, W666 and W680 (lower panel: lane
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18) together, with the remaining Trps mutated to Ala. Here, the W653/666/680A con-
struct showed binding comparable to wt (lower panel: lane 16), whereas the W623/634A
construct completely lost its affinity for Ago2.
This results leads to the conclusion that W623 and W634 are necessary and sufficient
for binding.
Figure 2.8.1: The TNRC6B
599-683 :Ago2 interaction
is mediated by Trps. Upper
panel: Input for pull-down
assay with respective mutants
indicated above. Lower panel:
Ago2 precipitation by GST-
pull-downs with TNRC6B
599-683 mutants. Mutations
W623A and W634A impaired
binding, whereas W653A,
W666A and W680A had no
effect. The combination of
W623 and W634 are sufficient
to restore binding to wt level.
Comparing those results with the peptide array, we noticed that peptide E11 contain-
ing only one Trp (W623) was actually able to bind Ago2 alone, whereas peptide E14
containing only W634 was not. The reason for this might be that the pull down assay
was not appropriate to detect this transient interaction. Nevertheless, the results from
the peptide array are consistent with the NMR titration results, were the region sur-
rounding W623 was stronger affected than the region flanking W634. This suggest that
W623 binds with a higher affinity, whereas W634 assists binding. However, binding in
the context of a larger fragment might be different.
2.9 Mapping TNRC6B Contacts on the Surface of
Argonaute 2
Having characterized the binding of Ago2 to TNRC6B, we next located the interaction
site of TNRC6B on the Ago2 surface. Thus, we subjected the TNRC6B 599-683:Ago2
complex to chemical crosslinking followed by mass spectromic analysis [88]. Therefore,
both proteins were purified to high homogeneity (Figure 2.1.5 A and Figure 2.1.1) and
crosslinked by incubation with isotope-labeled disuccinimidyl suberate (DSS). DSS is an
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11 Å crosslinker that contains an amine-reactive N-hydroxysuccinimide (NHS) ester at
each end, reacting with primary amines e.g. in Lys side chains. Crosslinking efficiency
was monitored by SDS-PAGE (Figure 2.9.1 A). The sample was loaded on a gelfiltration
column and a defined complex was slightly shifted towards higher molecular weight in
comparison to Ago2 alone, whereas free TNRC6B 599-683 and impurities were separated
(Figure 2.9.1 B). The pure complex was again visualized by coomassie staining after
SDS-PAGE (Figure 2.9.1) suggesting that the chemical crosslink was efficient and that
crosslinked proteins can be used for further analysis.
Figure 2.9.1: Crosslinking of TNRC6B 599-683:Ago2. A) SDS-PAGE of crosslinked TNRC6B
599-683:Ago2 complex with defined DSS concentration before (crosslink) and after (GF peak) separation
by SEC. The purified sample was subjected to MS analysis. B) After crosslinking of TNRC6B 599-681
and Ago2 the complex was separated from free TNRC6B 599-683 (blue line) and is slightly shifted
towards lower elution volume in comparison to free Ago2 (light blue line).
The crosslinked complex was digested with Lys-C and trypsin and finally analyzed
my MS as described in [88][214]. The analysis revealed 35 intra- and 5 intermolecu-
lar crosslinks that are summarized in Table 2.9.1.
The intermolecular crosslinks connecting TNRC6B and Ago2 are illustrated in Fig-
ure 2.9.2 A. Four Lys of Ago2 crosslinked with three Lys of TNRC6B 599-683 in different
combinations. However, K648 on TNRC6B 599-683 seems to be preferred. All Lys on
TNRC6B are positioned C-terminally of the interacting region we identified before.
For Ago2, intermolecular crosslinks were mainly observed in the PIWI domain, which
corresponds to literature. Lys K655, K693 and K844 are exposed on the surface of the
PIWI domain whereas K425 is a part of a linker between N-terminal and MID domain,
although it is close to the PIWI domain. Recently a crystal structure of Ago2 was pub-
lished [188]. The authors succeeded to co-crystallize Ago2 with two Trp molecules bound
to the surface of the PIWI domain. This is in good agreement with the data we have
obtained in the pulldown experiment. Here, we reported that two Trps next to each
other within a sequence are necessary and sufficient for binding.
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Table 2.9.1: Table of crosslink pairs identified by MS. Listed are 5 intermolecular (highlighted in
violet) and 35 intramolecular crosslinks detected the TNRC6B 599-683:Ago2 complex by MS. Analysis
of the crosslinks was performed by Dr. Franz Herzog.
Strikingly, all Lys identified by crosslinking are in close proximity to those Trps (Fig-
ure 2.9.2 B, crosslinked Lys in violet).
Figure 2.9.2: Crosslink map of TNRC6B 599-683:Ago2 analysis. A) The crosslink map il-
lustrates the crosslinks found between Ago2 and TNRC6B 599-683 (violet) and the Ago2 intramolec-
ular crosslinks (black dashed lines). Upper panel: Domain organization of Ago2: N-terminal domain
(orange), PAZ domain (blue), MID domain (purple) and PIWI domain (green). Lower panel: Lys
crosslinked in TNRC6B 599-683 are highlighted in violet. B) Surface presentation of Ago2 crystal struc-
ture (PDB: 4EI1) aligned with Trp (cyan) co-crystallized (PDB: 4EI3). Lys on Ago2 that crosslinked
with TNRC6B Lys are highlighted in violet. All other Lys present in the Ago2 sequence are highlighted
in salmon to show possible crosslinking sites.
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To illustrated the availability of Lys that could possibly react with the crosslinker, all
surface exposed Lys on Ago2 are highlighted in pink. We assume the distance between
Cα atoms of crosslinked Lys to be not more than 30 Å [88], calculated from the length
of the DSS spacer (11 Å), the length of each Lys side chain (two times 6.5 Å) and an
error due to the Lys side chain flexibility that was estimated to 3 Å. Since there are Lys
available for crosslink above the Trp binding site that did not react, TNRC6B 599-683
most likely binds below the Trp binding site.
Together, we revealed by crosslinks followed by mass spectromic analysis that TNRC6B
599-683 specifically binds a patch on the surface of the Ago2 PIWI domain and thus,
provide the first structural insights into the interaction of a longer TNRC6B fragment
with Ago2.
2.10 Model of TNRC6B - Argonaute 2 Interaction
Combination of all data obtained by the peptide arrays, biophysical and NMR experi-
ments as well as the crosslinks allows us to postulate a model of the binding mechanism
of TNRC6B and Ago2 (Figure 2.10.1).
Figure 2.10.1: Schematic model of Ago2:TNRC6B 599-683 binding mode. In a first step,
TNRC6B 599-683 binds with its first Trp (W623) to one Ago2 Trp binding pocket. All Lys in the
TNRC6B 599-683 sequence are flexible and can reach Ago2 Lys for crosslinking. In a second step
binding of the second Trp (W634) to the other pocket completes the affinity.
The TNRC6B 599-683 peptide probably binds with its first Trp (here W623 correspond-
ing to PDB: 4EI3 W901) to one Trp binding pocket on Ago in an initial step. W623 has
been shown to offer a stronger interaction with Ago2 both in the peptide array and in the
NMR titration experiments. At this stage, the second Trp (here W634 corresonding to
PDB: 4EI3 W902) would still be flexible and thus, all Lys come in appropriate distance
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for crosslinking their identified partner Lys. In a last step the second Trp binds to the
other pocket, fixing the peptide in its orientation resulting in full affinity.
To illustrate how the TNRC6B 599-683 fragment would bind Ago2, we loaded the Ago2
structure bound to two Trps (PDB: 4EI3) in the program coot [48]. On the basis of
the Trp positions we completed the remaining polypeptide chain of TNRC6B 599-689,
corrected it for bond angles, plane errors and rotamer positions (Figure 2.10.2). The
shortest way for the 10 aa polypeptide linker from one to the other Trp was assessed to
be spanning below the Arg nose sticking out of the Ago2 surface.
Figure 2.10.2: Model of Ago2:TNRC6B 599-683 interaction. TNRC6B 599-683 wraps along
the surface of Ago2 bound through two Trp in hydrophobic pockets.
If we now take a closer look at the TNRC6B polypeptide, some requirements for efficient
binding become obvious. First, the inner neighbors of the Trps do not necessarily have to
be Gly but rather small aa, otherwise proper binding to the Ago2 pocket is not ensured.
Second, the linker polypeptide sequence between both Trps must have a certain length,
to span from one site to the other, favoring the unstructured nature and flexibility of
the protein.
In conclusion, this model illustrates that the TNRC6B 599-683 is bound transiently to
the PIWI domain of Ago2 through two Trps, with the spacing polypeptides between the
two Trps spanning below the nose.
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Ago proteins are viewed as key players in small RNA-guided gene-silencing pathways
in almost all eukaryotes. The association of GW182 proteins with Ago proteins is es-
sential for efficient repression [52][43][146][175]. Thereby, GW182 binds via evolution-
ary and functionally conserved GW-repeat motifs to the PIWI domain of Ago proteins
[203][52][4][126][29][45], providing a binding platform for downstream silencing events
[235][231][224][201][175][126][92][57][51][43][31][28][17]. The functional relevance of this
interaction has been well established, whereas the mechanism beyond the interaction
itself remained elusive.
In this study, we dissected the role and nature of TNRC6B GW-motifs in Ago2 binding
and mapped the binding sites using biophysical and biochemical approaches. Finally,
we defined a model on the binding mode of both proteins.
3.1 Protein Properties
Prior to in vitro studies, recombinant TNRC6 as well as Ago protein needed to be ac-
quired. TNRC6 purification was challenging since full length proteins or longer con-
structs seemed to be unstable upon purification, even with high concentration of pro-
tease inhibitors. This is pertinent to the recognition that intrinsically disordered proteins
(IDPs) are extremely susceptible to proteolytic degradation in vitro [205]. It has been
shown that the half-life of a protein rather negatively correlates with the length of the
polypeptide chain and with various measures of structural disorder than with the pres-
ence of degradation signals [206]. Consistent with this, purification of globular domains
(RRM) and smaller conserved sequence sections of TNRC6 proteins was successful.
The sequence of GW182 proteins responsible for Ago binding shows strong similarity
to FG-nucleoporines except for exhibiting WG instead of FG repeats. Over the last
decade, FG-nucleoporines were intensively studied. Those proteins are intrinsically dis-
ordered and crucial for building a permeability barrier in the nuclear pore complex [65].
In a recent study, RNA-binding-proteins (RBPs) offering low complexity regions that
contain several YG-repeats were investigated [104]. Both studies showed that at high
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concentrations the protein sequences containing F/YG-repeats were able to form so-
called hydrogels in vitro.
Notably, in this work at very high concentration of TNRC6B 599-683 to about 10 mM,
reversible formation of a hydrogel was observed (data not shown). However, those re-
sults were not reproducible. Thus, besides degradation, the full length protein being
even more prone to hydrogel formation, could be stuck during the purification proce-
dure, e.g. in the concentrator.
Ago proteins were obtained in low yield, however, in high purity. Attempts to reduce
Ago2 to the minimal TNRC6B binding domain were not successful since expression of
all constructs tested yielded insoluble protein. The results of analytical limited proteol-
ysis implies that the protein is highly resistant towards proteolytic digestion. This is in
accordance with a recent publication [47]. The authors separated Ago2 complexed with
small RNAs from its unloaded species and showed that, after digestion, only unloaded
protein was proteolysed, whereas the complex was stable.
3.2 Argonaute 2 Binds to Distinct Tryptophan - containing
Motifs on TNRC6B with Different Affinities
Several studies contributed on the definition of the Ago binding site on GW182 proteins.
It is known that the N-terminal GW-rich region [8][203][201][45][4][52][203], together
with the Ago PIWI domain [8][148] are crucial for the interaction [126].
3.2.1 Definition of the Argonaute 2 Binding Site on TNRC6B
We used a peptide array to obtain comprehensive information about the number and
affinities of Ago2 binding sites on TNRC6B. We found multiple distinct regions within
the TNRC6B sequence that allow Ago2 binding. All peptides possessed at least one
Trp whereas the remainder sequence composition seemed to be random. Within those
peptides, we identified three sites having a strong affinity as well as several sites with
medium, weaker and no affinity. Most of the binding sites were located in the N-terminal
part of TNRC6B, although a Trp-containing aa stretch in the C-terminal part comprises
weak Ago2 affinity, too. The three hotspots cover the aa TNRC6B 467-501, TNRC6B
612-641 and TNRC6B 767-791.
TNRC6B 612-641 corresponds to a WG/GW-rich region of GW182 that was before
described as evolutionary conserved platform for Ago recruitment. Baillat et. al [4]
reported that this region (termed domain I) is necessary and sufficient for the association
of TNRC6B with Ago2 and that deletion of this region abrogated binding. These results
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are partially in contrast to our findings, since the authors observed that one specific
domain is responsible for the interaction, whereas we find multiple distinct binding sites.
Supporting our results, other investigators found that in context of the full length protein,
this region (termed motif I) of D. melanogaster (Dm) GW182 seems to be the major
binding site for Ago1 [51]. Deletion of a single GWG-repeat strongly impaired binding.
However, the authors conclude that additional GW-repeats strengthen the interaction
by providing low affinity binding sites.
A report in context of full-length TNRC6A, B and C [117] showed that two conserved
motifs (termed motif I and II) provide major binding sites in TNRC6C with additional
repeats providing low affinity binding sites. In contrast, the impact on Ago interaction
upon deletion of motif I and II in TNRC6A and TNRC6B isoform 1 was marginal. This
is in accordance with our data showing that multiple GW-repeats contribute to the
interaction.
Similarly, it was demonstrated that three fragments within TNRC6A that correspond
to motif I, motif II and the Ago-hook were sufficient for Ago binding. Although, in our
study, peptides of motif II offered only medium binding affinity.
In agreement with the results of Lian et al. [126], we did not only observe binding
of the N-terminal repeats in the peptide array, but also for a stretch lying in the C-
terminal sequence. Due to the small number of GW repeats and thus lower affinity, this
interaction could most probably only be detected in a more sensitive peptide array and
not in pull-down assays.
3.2.2 Role of Tryptophan Residues in the Argonaute - TNRC6B
Interaction
In previous studies Trps were shown to play an important role in Ago:GW182 binding
[45][203][201]. We now strengthened those results and identified Trps as key residues
mediating the interaction. Substitution of Trp to Ala, Tyr, Leu and Arg completely
abolished binding. Interestingly, substitution of Trp to Phe, did not prevent the peptide
from interacting with Ago2, even though the affinity was alleviated. This suggests that
the benzole ring, abundant in both Trp and Phe, mediates the major interaction possibly
by sticking into a binding pocket on Ago. This would be prevented by the additional
hydroxy group present in Tyr. In contrast, replacement of Trp by Phe was shown before
to abrogate binding [45][203] what is, however, not in accordance with a recent report
where Ago was cocrystallized with phenol [188].
We further found that the context of the Trp also contributes to the interaction. In
the first peptide array it appears that several aa before and after the Trp is needed for
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optimal binding. Substitution of the complete sequence or only parts (except for the
Trp) by Gly or Ala lead to very low affinity, however, binding was still detectable. Here,
the polyGly or polyAla peptide probably adopted secondary structure. Thus, its rather
the structural property of the entire peptide than the absence of specific residues that
determines the binding capacity. This is supported by the fact, that the binding affinity
was not affected upon substitution of single Trp flanking aa. This is in contrast to an
experiment, were it was shown that Gly are indeed necessary as well as substitution of
specific residues affected binding [203].
With this information we tried to identify a general Trp-motif comprising efficient Ago
binding. Alignment of the peptides did not reveal a conserved motif except for the
presence of at least one Trp. It appeared that the presence of two Trps increased the
affinity. However, we were not able to identify a binding motif surrounding Trps that
engage in Ago binding.
Taken together, our results confirm and extend the knowledge about the binding site of
Ago2 on TNRC6B and the role of Trps. The focus on investigation of GW/WG-repeats
has to be corrected towards Trp-repeats, since we have found that a flanking Gly is
preferred but not absolutely necessary for binding. Instead, it appears that Trp neighbors
have to be rather small, hydrophilic residues. Furthermore the aa composition plays a
role in terms of structural integrity. Generally, comparison of reports on GW182:Ago
interaction leads to the assumption that binding sites on GW182 proteins can differ
species- and homologue-wise. Moreover the method used for the experiments seems to
influence the results.
3.3 The Argonaute 2 Surface Reveals Potential Binding
Interfaces
In the first part of the study, we characterized the Ago2 binding site on TNRC6B. In-
spection of the Ago2 surface reveals features that might be involved in TNRC6B binding.
Figure 3.3.1 shows the crystal structure of Ago2 (PDB: 4EI1) with the two bound Trps
(PDB: 4EI3) aligned. In Figure 3.3.1 A, hydrophobic residues are colored in orange.
The two Trp binding pockets exhibit a clearly hydrophobic character, however, some
other hydrophobic patches are visible that could serve as binding sites for additional
hydrophobic interactions of the peptide. Surface charges (Figure 3.3.1 B) are equally
distributed all over the protein. Besides the positively charged inner protein core, which
is involved in miRNA binding, no defined charged patches can be observed. A small
pocket below the Trp binding site is positively charged originating from Arg/Lys inside
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the PIWI domain. This pocket could play a role in binding negatively charged or phos-
phorylated aa in the vicinity of bound Trps. Ago2 sequence conservation was plotted on
the surface using the ConSurf server illustrated in Figure 3.3.1 C. In contrast to the aa
forming the inner core of the protein, the aa lying on the Ago2 surface are less conserved.
An exception are the aa forming the Trp binding pockets and a stretch of aa lying in a
groove below the Trp binding pocket comprising the hydrophobic and positively charged
pocket described before. This region might play a role in GW18 binding, although it
could be an interaction site for another protein.
Figure 3.3.1: Surface properties of Ago2. Surface presentation of Ago2 crystal structure (PDB:
4EI1) aligned with Trp (cyan) cocrystallized (PDB: 4EI3). A) Hydrophobic residues are colored in
orange. A hydrophobic patch is indicted by an arrow. B) Electrostatic potential. A positively charged
pocket is indicated by an arrow. C) Conservation. Conserved aa stretch is indicated by an arrow.
Before the crystal structure of Ago2 was obtained, several groups tried to determine the
GW182 binding site on Ago by mutational analysis. Till et al. [203] mutated several
residues in the PIWI domain as well as in the MID domain of Ago2 to Ala, leading
to strong (orange) and mild (light orange) decrease in affinity (Figure 3.3.2). Residues
R583, R647 and K660 are directly involved in formation of the hydrophobic Trp binding
pocket, thus, mutation of those residues completely abrogates binding. Other residues
with strong and mild impact are not directly involved in the Trp interaction but might
destabilize the surface conformation leading to impaired binding. Residues F470 and
F505 (termed F2V2 mutant) are indicated in yellow. Here, single residue mutation did
not impair the interaction [52] whereas double substitution completely abolished binding
[52][148], probably due to aggregation of the MID domain. GW182 interaction to Ago
has been described to be independent of miRNA binding [182]. Thus, loss of binding
by mutation of residues in the MID domain is probably not a consequence of impaired
miRNA binding but rather results from a conformational change of the MID domain
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towards the PIWI domain or aggregation. Mutation of residues comprising the positively
charged pocket described above (Figure 3.3.1 B) K533 and R812 strongly affects binding.
Since these mutations are far away from the identified Trp binding pockets, those results
might point towards an additional binding site, maybe in the groove described above
between PIWI and MID domain Figure 3.3.1. Some of the mutations showed by Till et
al. were verified in a later studies [51][52][13].
Figure 3.3.2: Ago mutations impairing GW182 binding. Ago2 crystal structure (PDB: 4EI1)
aligned with Trp (cyan) cocrystallized (PDB: 4EI3). A) Mutations with strong impact on GW182
binding are colored in orange, mutations with mild impact are colored in light orange and residues of
the F2V2 mutant are colored in yellow. B) close up of a). C) surface presentation of A) displaying
residues important for Trp binding. D) close up of C).
3.3.1 Implications of Species Specific Surface Characteristic on GW182
Binding
We suggest that the residues between both Trp are spanning below the Arg residue
(R658). Thus, we were interested whether this residue plays a role in positioning the
peptide. Figure 3.3.3 A shows a sequence alignment of different species covering Ago2
R658. This residue is only conserved in higher vertebrates as human, mouse and frog.
Inspection of the surface composition of available Ago structures (Figure 3.3.3 B) reveals
that the hydrophobic pockets needed for anchoring the two Trps are only available in
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the structures of human proteins (PDB: 4EI1 and 4F3T).
Figure 3.3.3: Surface characteristics of Ago structures from different species. A) alignment
of the sequence surrounding Ago2 R658 with different species. B) Surface presentation of Ago structures
from different species. Hydrophobic residues are colored in orange, Ago2 R658 and its corresponding
residues are highlighted in red.
Neither structures of yeast (Kluyveromyces polysporus), fungi (Neurospora crassa), eu-
bacteria (Thermus thermophilus) or bacteria (Aquifex aeolicus) comprise comparable
GW182 interaction sites. This is in agreement with the results obtained in this study
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were we showed that pfAgo cannot interact with TNRC6B.
According to that, only higher eukaryotes are able to bind GW182 and exert downstream
pathways. This is reasonable since GW182 homologues are only known in miRNA-
mediated gene silencing of higher eukaryotes. In contrast, Till et al. found that the
archaeal Archaeoglobus fulgidius PIWI protein directly bound to a TNRC6B fragment
[203]. However, it might be possible that the Archaeoglobus fulgidius PIWI protein
functions in a sRNA-mediated gene silencing-like pathway interacting with other GW-
proteins.
3.4 TNRC6B Binds to the Argonaute 2 PIWI Domain
Through a Combinatorial Tryptophan - Motif
3.4.1 Tryptophan Position
Having observed that besides Trp no other aa directly interacts with Ago in the peptide
array, we confirmed our assumption by STD-NMR measurements on an atomic level.
Measurements of peptides containing two Trps show that both Trps interact with Ago2.
However, we cannot tell apart which peaks originated from which Trp, and also not,
whether both Trps bind at the same time or successively. In agreement with that, the
Ago2 crystal structure [188] confirms that both Trps can bind at the same time.
Exact inspection of how the two Trps are bound to the pocket (Figure 3.4.1) gives
evidence that W901 is stronger coordinated to surrounding Ago residues than W902.
However, in context of a peptide, the exact position of the Trps might slightly differ.
Figure 3.4.1: Trp coordination in Ago2 binding pockets. Different coordination of Trps A) W901
and A) W902 in the Ago2 binding pocket (PDB: 4EI3).
Interestingly, comparing STD-amplification factors of protons within the indole ring
shows that protons Hη2 and Hζ2 possess the highest values for all peptides tested (ex-
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cept for peptide F9 that had generally a very weak affinity), thus probably being closest
to Ago.
If we now reconsider the published Ago2 structure and the positions of the two Trp
bound, those results are reasonable. Both Trps stick with their benzole rings into Ago,
thereby allowing an efficient transfer of magnetization to Hη2 and Hζ2. Here, the re-
sults from the second peptide array, were we showed that Phe but not Tyr instead of
Trp allows binding, fit very well. Tyr exhibits an additional hydroxy group at the top
of the benzole ring, thereby abolishing binding either sterically or due to its charge. In
contrast, Phe features the same benzole ring as Trp making it possible to perform equal
interactions. However, it lacks the additional affinity mediated by the pyrrol part, thus,
showing reduced affinity.
To investigate, which TNRC6B 599-683 residues are affected upon Ago2 binding we
performed NMR titration experiments. We found that only 2 out of 5 Trps undergo
chemical shift perturbations and intensity changes. W623 is highly affected whereas the
impact on W634 is milder. This leads to the conclusion that W623 binds stronger to
Ago than W634, in agreement with Figure 3.4.1.
Pulldown assays confirm an important role of W623 and W634 within TNRC6B 599-681
shown by NMR titration experiments, since binding is completely abolished after substi-
tution of Trp by Ala. According to a study by Takimoto et al. [201], mutation of residues
corresponding to TNRC6B W623 and W634 in TNRC6A 431-520 completely abolished
binding to Ago2 in a pulldown assay, whereas substitution of the Trp corresponding to
TNRC6B W653 had no influence. Similarly, in further pulldown assays using TNRC6A
431-520 and TNRC6B 584-673, the interaction of the W623A mutant was completely
abolished, although W634A only scarcely interacted with Ago2. Differences for W634A
binding within the study and also to our results might have methodical reasons. How-
ever, this data match to the titration experiments, were we observed a stronger binding
for W623. In contrast to the study by Takimoto et al. we did not only show that
substitution of a single Trp to Ala abrogates binding but also, that this two Trps act
synergistically and are sufficient for wt binding.
3.4.2 Trp Spacer Length
Investigation of the three binding hotspots identified by the peptide array reveals that the
spacer between the two Trp for all hotspots is exactely 10 aa in length. This prompted us
to systematically compare spacer lengths within TNRC6B (Figure 3.4.2). Indeed, most
of the other spacing regions are either longer or shorter. In total, we find seven regions
with a Trp distance of 10 aa, three of them are our high affinity binding sites. Inspection
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of the other spacers shows that they either contain hydrophobic, aromatic residues (Tyr)
which might lead to a hydrophobic collapse of the peptide or a Pro residue, which limits
the flexibility of the peptide spacer, thereby hindering the Trp to properly access the
binding pocket. This suggests that a certain spacing of Trp side chains may suffice to
provide significant affinity to Ago2.
Figure 3.4.2: Spacing between TNRC6B Trps. Sequence of TNRC6B with all Trps colored in
blue. The aa distance between each Trp is indicated by a black line, with the sequence upstream of
W623 pointed out with a bold line. The binding hotspots are highlighted in gray.
In summary, combination of our data from the peptide arrays, NMR measurements,
pulldown assays and crosslinking allows to define some requirement for binding Ago:
First, the Trp neighbor must be a rather small, hydrophilic residue. Second, the Trp
containing peptide must be flexible for proper Trp accessibility. Third, binding affinity is
enhanced by simultaneous contacts of two Trp side chains separated by defined spacing.
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3.4.3 Relation to Known Protein Sequence Motifs
Remarkably, in NMR titration experiments not only the region surrounding those two
Trps shows signs of binding, but also some residues N-terminally of that region.
In post-transcriptional mRNA regulation, many proteins were shown to contain short
linear interaction motifs (SLiM) [42] (about 6-11 aa) in disordered protein regions that
mediate low µM affinity interactions to globular domains of other proteins. Many of
them are unfolded in solution, however, parts of the protein that are close to the motif
adopt secondary structure upon binding. This fold can then exert additional affinity
and play a role as specificity factor. Similarly to GW182 proteins, those motifs occur in
multiple copies to mediate high affinity interactions.
Recently, a direct interaction between the decapping factor DCP1 and the exonuclease
XRN1 was identified, which couples mRNA decapping to 5’ exonucleolytic degrada-
tion [18]. The authors presented a NMR structure oft the D. melanogaster proline-rich
DCP1-binding motif (DBM) of XRN1 bound to the hydrophobic cleft of the DCP1
EVH1 domain. The XRN1 DBM peptide is unfolded in the free state but, after binding,
partially folds upstream to its proline-rich sequence into a helix. This leads to additional
contacts of the XRN1 DBM peptide on DCP1 EVH1 that contribute to affinity, speci-
ficity and determination of the peptide orientation. It was further discovered that the
XRN1 motifs required for DCP1 binding differ in different species (D. melanogaster and
H. sapiens), however, fulfilling the same function. This evolutionary plasticity might
also explain contradicting results when mapping the Ago binding site on GW proteins
in different species.
Several other studies report similar results, e.g. the crystal structure of the human DDX6
C-terminal RecA-like domain bound to a highly conserved FDF sequence motif in the
decapping activator EDC3 [208] or the yeast EDC3 LSm domain in complex with a short
helical leucine-rich motif (HLM) from DCP2 [67].
In agreement with that, TNRC6B 606-621, lying upstream to W623 and W634, is not
only affected in NMR titration experiments but the very N-terminus of this part (residues
VLQTLLS) also shows a greater flexibility in relaxation experiments in comparison to
the other residues.
The european linear motif (ELM) data bank lists this sequence as nuclear receptor box
motif (LXXLL) that confers binding to nuclear receptors. Usually, this motif is exposed
and resides in natively disordered polypeptides.
As an example, Figure 3.4.3 shows the structure of the glucocorticoid receptor ligand
binding domain bound to a TIF2 coactivator motif (PDB: 1M2Z).
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Figure 3.4.3: Exemplary crys-
tal structure for LXXLL mo-
tif binding. Crystal structure
of the glucocorticoid receptor lig-
and binding domain (gray) bound
to a TIF2 coactivator motif (cyan)
(PDB: 1M2Z). Residues comprising
the charge-clamp are highlighted in
red (Glu) and blue (Lys).
The LXXLL peptide forms an alpha helix that binds via its three Leu to a hydrophobic
groove positioned by a so-called charge-clamp.
TNRC6B 599-681 is unfolded in free form and might also adopt secondary structure
after binding. The VLQTLLS stretch could potentially form an alpha helix as shown
in Figure 3.4.3, positioned by the negatively charged D599 and the positively charged
R610.
Taking a closer look at the TNRC6B sequence, the distance upstream to W623 to the
next Trp containing the VLQTLLS stretch is remarkably big in comparison to the spac-
ing between the Trps in surrounding regions, allowing formation of secondary structure
(Figure 3.4.2).
Corresponding to considerations about the Ago2 surface above, the groove between PIWI
and MID domain below the Trp binding pockets might be a possible binding site for this
additional interactions. Extra contacts might serve as specificity factor towards other
GW regions in Ago binding. e.g. the Not1 binding sites on GW182 identified in two
studies [28][57] contain Trps that are important for Not1 interaction, but, at the same
time also have affinity towards Ago as shown in Figure 2.3.1. Here, discrimination of
Trp-motifs that are either essential for Ago or Not1 interaction would help to further
explain GW182 function.
However, another explanation for the results of the titration experiments is that due to
the higher flexibility of this part only the dynamic property changes. This would result
in lower signals, even if the part is not directly involved in binding. To get a clear picture
about the role of this region in Ago binding, further experiments like pulldown assays
with protein mutants or NMR titration experiments with much higher concentrations in
order to get the structure of bound TNRC6B 599-681 would be required.
3.5 Functional Implications
It has been shown that one Ago protein cannot associate with multiple GW182 molecules
[201]. However, we demonstrated that one GW182 protein can potentially bind multiple
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Ago proteins as confirmed by other reports [4][45]. In our study, TNRC6B was able to
interact with all four human Ago proteins, thus, not having a preference for a specific
Ago protein [117].
We found binding of TNRC6B 599-683 and Ago2 with an equilibrium dissociation con-
stant in a low µM range, what is consistent for an interaction of only a small number of
residues. The weak affinity might suggest that GW182-Ago binding is a dynamic process
with a rapid exchange. This kinetically enhances complex formation which would permit
efficient recruitment of the translational repression machinery to the mRNA for several
Ago proteins by a single GW182 but also allows the disassembly at a later stage.
Ago and GW182 are enriched in cytoplasmic GW/P-bodies [56][55][194]. This foci are
sites of mRNA degradation and silencing [168][50]. Our observation, that TNRC6B
formed a hydrogel at very high protein concentrations, could be interpreted in a way that
the long unstructured protein forms soluble aggregates at certain conditions. Thereby,
it interacts with other GW182 and RBPs [104], which then become visible as GW/P-
bodies. Thus, all factors needed for silencing can assemble and are spatially compressed.
Hydrogel formation has been shown to be phosphorylation dependent and it is specu-
lated that the dynamics are regulated by post translational modifications [84]. Since
GW182 is phosphorylated in vivo [55], it is tempting to speculate hydrogel formation to
be a major determinant in GW182-dependent gene regulation. However, clarifying this
process requires further studies.
Moreover, the TNRC6B599-683 construct, that was characterized in this work might
be used as general inhibitor of Ago-GW182 (or GW protein) interaction. Upon further
investigation, this fragment could be applied in basic research or medical therapy to
prevent downstream processes in miRNA-mediated gene-silencing.
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4.1 Material
4.1.1 Consumables and Chemicals
All chemicals were purchased from Amersham Biosciences (Buckinghamshire, UK), Bio-
rad (Hercules, USA), Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), Qia-
gen (Hilden, Germany), Roche (Basel, Switzerland), and Sigma-Aldrich (Munich, Ger-
many), unless stated otherwise. Enzymes, nucleotides and molecular weight markers
were purchased from New England Biolabs (Ipswich, USA), Invitrogen (Darmstadt, Ger-
many), and Fermentas (Burlington, Canada). Components for bacterial growth media
were ordered from Becton Dickinson (Heidelberg, Germany). Insect cell media were ob-
tained from Invitrogen and Thermo Scientific (Waltham, USA). Equipment for liquid
chromatography was purchased from GE Healthcare (Munich, Germany). DNA oligonu-
cleotides were synthesized by Metabion (Martinsried, Germany), and Thermo Scientific.
Peptides were provided by Peptide Specialty Laboratories (Heidelberg, Germany), and
the peptide service of the Core Facility at the Max Planck Institute of Biochemistry
(Martinsried, Germany). Peptide arrays were obtained from JPT Peptide Technologies
(Berlin, Germany).
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4.1.2 Oligonucleotides
Oligonucleotides for cloning:
Oligonucleotides for Quickchange Mutagenesis:
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4.1.3 Plasmids
All plasmids created are based on the following vectors:
Cloned plasmids:
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4.1.4 Antibodies
4.1.5 Bacterial Strains and Cell Lines
Bacterial strains:
Cell lines:
4.1.6 Media and Buffers
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4.2 Methods
4.2.1 Molecular Biology Methods
Standard molecular biology methods were performed as described by Sambrook et al.
[186]. Genes were amplified from template DNA using PhusionTM DNA Polymerase
(Finnzymes, Espoo, Finnland), analyzed by agarose gel electrophoresis in 1x TBE run-
ning buffer. After staining with GelRed (Biotium), PCR products were purified with
the NucleoSpin gel and PCR clean-up kit (Macherey Nagel, Düren, Germany).
For conventional cloning, vector DNA and PCR products were digested with the re-
spective restriction enzymes and ligated using T4 DNA Ligase (Fermentas, Burlington,
Canada) according to the manufacturer’s instructions.
For ligation independent cloning (LIC) (Aslanidis and deJong, 1990) the pEC series of
vectors generated by Jerome Basquin and Florence Martin in the laboratory of Elena
Conti was used according to the following protocol.
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Processing of insert:
Component Amount
gel purified PCR product 600 ng
T4 DNA Pol. buffer (10x) 2 µl
dATP (25 mM) 2 µl
DTT (100 mM) 1 µl
T4 DNA Pol. LIC qualified (Novagen) 0.4 µl
H2O add to 20 µl
Vector processing:
Before processing, 2 ug vector were linearized by digestion with 60 u of SacII (or 20 u
ZraI for 3C LIC vectors) and gel purified
Component Amount
linearized vector 450 ng
T4 DNA Pol. buffer (10x) 3 ul
dTTP (25 mM) 3 µl
DTT (100 mM) 1.5 µl
T4 DNA Pol. LIC qualified (Novagen) 0.6 µl
H2O add to 30 µl
After incubation for 30 min at RT, reaction mixes were inactivated at 75°C for 20 min.
For annealing, 2 µl of processed insert and processed vector were incubated for 10 min
at RT. 1 µl EDTA (25 mM) was added and the mix was incubated for 10 min at RT.
For transformation into E. coli 2 µl were used.
Point mutations were introduced using the QuickChange II site directed mutagenesis kit
(Agilent Technologies).
Plasmids were transformed into chemically competent E. coli cells prepared according to
Hanahan, 1983 [85]. Isolation of plasmid DNA was carried out using the NucleoBond®
XtraMini Kit (Macherey Nagel, Düren, Germany). The success of the cloning procedure
was confirmed by DNA sequencing (Core Facility at the Max Planck Institute of Bio-
chemistry or Eurofins MWG Operon).
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4.2.2 Protein Expression
Protein Expression in E. coli
For all constructs in the present work, expression was first tested in small scale with
conditions. Expression levels were assessed by small-scale pull down experiments with
the appropriate affinity resin.
For large scale expression, colonies of freshly transformed BL21(DE3) Gold pRARE were
used to inoculate 20 ml LB medium supplemented with the respective antibiotics over
night. 3 l of LB medium were inoculated 1:1000 with preculture and then grown in
baﬄed Erlenmeyer flasks at 37°C under constant agitation (160 rpm). At an OD600 of
about 0.4 the culture was cooled to 18 °C. Expression was induced at an OD600 of 0.7
by adding 0.1 mM Isopropyl-β-D- thiogalactopyranosid (IPTG). After 10 h cells were
harvested (4400 x g, 15 min, 4°C), flash frozen with liquid nitrogen, and stored at -80°C.
For NMR spectroscopy experiments TNRC6B 599-683 was 15N13C-labeled during pro-
tein expression in minimal medium. As preculture, freshly transformed E. coli BL21
(DE3) Gold pRARE cells carrying the plasmid JP_P6 were grown in 20 ml medium
containing 1:1000 kanamycin (50mg/ml) and chlormaphenicol (34 mg/ml) over night at
37 °C. One liter of minimal medium supplemented 1:1000 with kanamycin (50mg/ml)
and chlormaphenicol (34 mg/ml) was inoculated with 5 ml of the preculture and grown
at 37°C to an OD600 of 0.8. After induction of expression with 0.1 mM IPTG, cells were
grown for 10 h, harvested (4400 x g, 15 min, 4°C), flash frozen with liquid nitrogen, and
stored at -80°C.
Protein Expression in Insect Cells
Recombinant baculovirus was prepared essentially as described in the Bac-to-Bac man-
ual (Invitrogen). A culture of 500 ml High Five cells with a density of 1x 106 cells/ml
was infected with 30 ml P2 viral stock and cultivated for 72 h at 27.5 °C with 85 rpm
shaking. Cells were then harvested (1000 x g, 20 min), flash frozen with liquid nitrogen
and stored at -80°C.
Culturing Mammalian Cells
Mammalian cells were cultured in DMEM at 37°C and 5%CO2. In order to split cells,
the medium was removed, cells were washed once with PBS and were detached by
treatment with Trypsin-EDTA (PAA, Pasching, Austria). Detached cells were pelleted
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by centrifugation at 200 x g for 5 min and plated on fresh plates.
For whole cell lysate preparation, cells were cultured to 80-90% density, washed three
times with PBS, scraped off and pelleted at 200 x g for 10 min. Cell pellets were flash
frozen in liquid nitrogen and stored at -80°C. 3 ml of cell pellet was then thawed on ice,
resuspended in 15 ml lysis buffer freshly supplemented with DTT and protease inhibitor
(Roche, Basel, Switzerland) by pipetting up and down and incubated on ice for 20 min.
Cell debris was pelleted by centrifugation (17000 x g, 10min, 4°C) and the supernatant
was transferred to a fresh reaction tube.
4.2.3 Protein Purification
Purification of proteins expressed in E. coli
Proteins were expressed in E. coli BL21 (DE3) Gold pRARE cells according to the pro-
tocol detailed above. All steps were carried out at 4 °C. Typically, 3 l of culture were
resuspended in GST-A buffer supplemented with one tablet of EDTA-free protease in-
hibitor cocktail (Roche, Basel, Switzerland) and 0.4 mM PMSF to a total volume of 100
ml. After sonication (4 x 4 min, amplitude 30%, output: 6), the lysate was clarified by
centrifugation (39000 x g, 30 min), loaded onto two 5 ml GSTrap columns (GE Health-
care) connected in series, equilibrated in buffer GST-A, and washed with 20 column
volume (cv) of GST-A. His-GST tagged protein was eluted in 5 cv of buffer GST-B. For
tag cleavage, a volume of 5 ml GST-A supplemented with 100 µg of 3C (PreScission)
protease was applied to the column. Both ends of the column were connected and the
flow rate was set to 0.3 ml/min for 10 h. Cleaved protein was eluted directly on a 5 ml
HisTrap column (GE Healthcare) collecting the flow through.
Proteins were filtered with a 0.22 µM filter, and concentrated by ultrafiltration with
an Amicon Ultra centrifugal filter (Milipore, Billerica, MA, USA). Finally, purification
was completed by size exclusion chromatography (Superdex 75 10/300 gl) carried out in
SEC buffer. Purified protein was usually concentrated to 5-10 mg/ml by ultrafiltration.
Quality was ensured by SDS-gel electrophoresis and UV-spectroscopy. Aliquots were
flash frozen in liquid nitrogen and stored at -80°C.
Purification of Proteins Expressed in Insect Cells
All steps were carried out at 4 °C. Insect cell pellets of 5 l culture were resuspended in
Ni-A buffer supplemented with one tablet of EDTA-free protease inhibitor cocktail and
0.4 mM PMSF to a total volume of 300 ml. After sonication (4 x 1 min, amplitude 30%,
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output: 6), lysate was clarified by centrifugation (39000 x g, 45 min) and applied onto a
XK16/20 column (GE Healthcare) filled with 5 ml of Ni-resin (GE Healthcare), following
three washing steps with buffers Ni-salt, Ni-ATP and 8% Ni-B and elution in 5 cv Ni-B.
For purification of Ago proteins, the eluate was supplemented with 100 µg of TEV pro-
tease and dialyzed against 2 l buffer SEC containing 2 mM EDTA. After incubation, the
sample was passed over a HisTrap column (GE Healthcare). Unbound flow through was
collected, concentrated and resolved by size exclusion chromatography (Superdex 200
10/300 gl) in SEC buffer. The protein was pure as assayed by SDS gel electrophoresis
and was concentrated to 1-5 mg/ml, flash frozen with liquid nitrogen and stored at 80°C.
4.2.4 Protein Biochemistry
Concentration Determination
Protein concentration was determined by measurement of the A280 using the NanoDrop
ND-1000 UV-Vis spectrophotometer (Peqlab) or by Bradford Protein Assay (Biorad,
Hercules, USA). The respective extinction coefficient was calculated with ProtParam
(www.expasy.org).
Gel Electrophoresis and Protein Visualisation
Depending on size, proteins were separated on 8% -19% sodium SDS-gels as described by
Laemmli, 1970 [116]. Coomassie staining of gels was performed with PageBlue protein
Staining solution (Thermo Scientific).
For silver staining gels were fixed in Silver fix buffer for 1 h and washed with buffer Silver
wash three times for 20 min . Silver thio buffer was applied for 1 min followed by rinsing
three times with water for 20 sec. After soaking with buffer Silver nitrate for 20 min,
the gel was rinsed with water two times for 20 sec. Developer (Silver dev) was applied
until the desired stain intensity was reached and the reaction was stopped by discarding
the developer followed by rinsing with water. The gel was then incubated in stopping
solution (Silver stop) for 10 min and transferred into water.
Analytical Limited Proteolysis
For analytical limited proteolysis 10 µl protein (0.6 mg/ml) were subjected to protease
of different concentrations (0.1 mg/ml, 0.01 mg/ml, 0.001 mg/ml) in SEC buffer. After
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incubation on ice for 30 min, the reaction was stopped by addition of 1µl 100 mM 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF). Samples were separated
by SDS-gel electrophoresis.
In Vitro Pull-down Assay
For each pulldown, the respective resin was washed two times (5000 x g, 1 min) with
water and two times with SEC buffer. For pull-down from whole cell lysate, an excess of
GST-tagged protein was bound to 50 µl Glutathione Sepharose 4B beads (GE Health-
care) for 1h at 4°C, washed three times with SEC buffer and added to 15 ml whole cell
lysate, followed by incubation for 3 h on a rotating wheel at 4°C.
Recombinant proteins were mixed in a total volume of 100 µl and incubated for 30 min
on ice. The resin was resuspended in SEC buffer, added to the protein mixture and
incubated for 1 h on a rotating wheel.
After incubation, the resin was washed twice with 1 ml SEC buffer and once with 1 ml
SEC buffer supplemented with additional 150 mM NaCl. The supernatant was removed
and bound protein was eluted either by boiling for 10 min in 5x SDS loading dye or by
addition of 50 µl SEC buffer containing 500 mM imidazole (for His-tagged proteins) or
50 mM GSH (for GST-tagged proteins). Eluted protein samples were analyzed by SDS
gel electrophoresis.
Peptide Array
Custom peptide membranes were obtained from JPT Peptide Technologies GmbH (Berlin,
Germany). For mapping protein interaction sites, the sequence of the desired protein was
synthesized as linear 20 meric peptides that are redundantly displayed overlapping in
15 residues. Peptides were C-terminally covalently bound to a cellulose-PEG-membrane
and N-terminally acetylated. Each of the spots carried approximately 5 nmol of pep-
tide. Prior use, the membrane was rinsed with a small volume of methanol, subsequently
equilibrated three times with TBS for 5 min and blocked with TBS containing 1% (w/v)
milk powder at RT. Before incubation with the protein, peptides were first checked for
unspecific interactions with antibodies used for detection of the bound protein. For this,
the membrane was incubated in TBS 1% (w/v) milk powder supplemented with Ago2
(11A9, 1.5 mg/ml) primary antibody diluted 1:1000 for 2 h. Following three washing
steps with TBS-T, the membrane was subjected to peroxidase-conjugated anti-rat anti-
body in TBS1% (w/v) milk powder according to the manufacturers instructions. Three
washing steps with TBS-T removed unbound antibody. Visualization was achieved using
the Pierce ECL substrate (Thermo Scientific). The membrane was then either exposed
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to light-sensitive films (GE Healthcare) or analyzed with the LAS-3000 mini imaging
system (Fujifilm, Düsseldorf, Germany).
Removal of bound antibody was achieved by incubation with buffer containing SDS and
ß-Me at 50°C for four times 30 min each. The membrane was subsequently incubated
in 10x PBS (3 x 20 min) followed by a washing step in TBS-T (20 min) and TBS (5
x 10 min). To analyze protein-protein contacts, prior to incubation with the primary
antibody, the membrane was incubated overnight at 4°C with 30 µg/ml Ago2 protein
in TBS with 1% (w/v) milk powder and washed three times in TBS-T for 5 min at RT.
Detection of bound Ago2 was achieved as described above. Quantification of signals was
carried out with the ImageJ software (http://rsb.info.nih.gov/ij/).
Circular Dicroism Spectroscopy
Secondary structure was analyzed by circular dicroism spectroscopy (CD)-spectroscopy.
Proteins were desalted into CD buffer using SEC (Superdex 75 10/300 gl). Protein
concentration was adjusted to a final concentration of 0.3 mg/ml and CD spectra were
recorded in a 0.5 mm cuvette on a JASCO CD-spectrometer ( 260-195 nm, 0.1 nm data
pitch, accumulation: 10, bandwidth 1nm, 20°C).
Dynamic Light Scattering
To determine the size distribution of particles in solution, dynamic light scattering (DLS)
was performed using a PDDLS/cool Batch 90T with PD 2000 DLS Plus detector sys-
tem. After centrifugation (20000 x g, 20 min), samples were mixed and measured in
a micro cuvette at 20°C. Ten measurements were recorded and the distribution of the
hydrodynamic radius was obtained from the autocorrelation function using the Precision
Deconvolve32 Software (Precision Detectors, Bellingham, USA).
Fluorescence Polarization
For fluorescence polarization (FP) measurements, TNRC6B 599-683 was Cys labeled
with Atto488 Maleimid (Atto-Tec). Measurements were performed at 20°C in 70 µl
reactions on an Envision Multilabel reader (Perkinelmer). Labeled protein was dissolved
to a concentration of 50 nM and incubated with increasing Ago2 concentrations in SEC
buffer. The excitation and emission wavelengths were 485 nm and 535 nm, respectively.
The dissociation constant was calculated by fitting the data with the one-site binding
model included in the program origin (OriginLab). The experiment was performed as a
duplicate.
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Crosslinking and Mass Spectrometry
The Ago2:TNRC6 B599-683 complex was crosslinked using isotopically coded disuccin-
imidyl suberate (DSS-H12/D12, Creative Molecules Inc.). To screen for ideal crosslink-
ing conditions, proteins were incubated in a 1:1 and 2:1 ratio with a concentration of 1
mg/ml for 30 min. 5 µg of the protein complex was mixed with with 25 mM DSS stock
solution dissolved in dimethylformamide (DMF, Pierce Protein Research Products) to a
final crosslinker concentration of 0 mM, 0.04 mM, 0.08 mM, 0.16 mM, 0.4 mM, 1 mM,
2 mM and 4 mM, respectively. After incubation (35 min, 30°C, 1000 rpm) the reaction
was quenched with 1 µl of 100 mM NH4HCO4 (15 min, 30°C, 1000 rpm). The sample
was mixed with 7 µl SDS loading dye and 2 µl were resolved on a SDS gel followed by
visualization of the bands by silver staining. The best crosslinker concentrations (0.16
mM and 0.4 mM in the 1:1 reaction) converted most of the protein to a higher molec-
ular weight complex but still avoiding oligomerization. For the final reaction 200 µg
(1mg/ml) of a 1:1 complex of Ago2 and TNRC6B 599-683 was mixed with DSS to a
concentration of 0.16 and 0.4 mM, respectively, and incubated at 1000 rpm for 35 min
at 30°C. The reaction was stopped by addition of NH4HCO4 to a concentration of 100
mM (15 min, 30°C, 1000 rpm). The crosslinked complex was applied to size exclusion
chromatography (Superdex 200 10/300 gl) in SEC buffer (with a NaCl concentration of
300 mM) and separated peaks of crosslinked protein (from 0.16 mM and 0.4 mM DSS
reaction) were pooled.
After treatment with two sample volumes of 8 M urea, proteins were reduced and alky-
lated using 5 mM Tris(2-carboxyethyl)phosphine (TCEP) and 10 mM iodoacetamide,
respectively. The sample was digested with Lys-C followed by trypsin after diluting the
sample to 1 M urea. Cross-linked peptides were enriched by size exclusion chromatog-
raphy and analyzed by MS as described previously [88]. Fragment ion spectra were
assigned to cross-linked peptides using xQuest [214].
4.2.5 Nuclear Magnetic Resonance
NMR Spectroscopy
Prior to nuclear magnetic resonance (NMR) measurements, 0.02 % NaN3 was added
to the sample containing 545 µM TNRC6B 599-683 (20 mM NaP (pH 6.5), 250 mM
NaCl, 10% D2O). Measurements for backbone assignments were conducted at 278 K on
a Bruker Avance III spectrometer with a magnetic field strength of 800 MHz, equipped
with a TCI cryogenic probe head. All data sets were processed using NMRPipe [39].
Sequential resonance assignment was obtained from three-dimensional HNCA, CBCA-
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CONH, and HNCACB experiments, employing constant time during 13C evolution [187].
Assignments have been found for 86 % of all residues (excluding prolines, 73 of 85). Miss-
ing assignments for residues other than prolines were Q605, L607, W623, G624, W666,
G667, N674, K677, W680, and G681. The three GW pairs could not be assigned unam-
biguously resonances present, due to the high flexibility and the resulting chemical shift
degeneracy. These ambiguously assigned Trp resonances do not exhibit intensity changes
upon Ago titration. Secondary structure analysis of the free protein was based on the
difference of measured 13Cα and 13Cβ chemical shifts to random coil chemical shifts
of the same nuclei [221]. Resonance assignments of TNRC6 peptides used in saturation
transfer difference NMR experiments, were obtained using two dimensional homonuclear
TOCSY, NOESY, and ROESY experiments [16][19][222]. Measurements for peptide res-
onance assignments were conducted at 298 K on Bruker Avance III spectrometers with
magnetic field strengths of 500 and 800 MHz, equipped with a TXI cryogenic probe
head. All assignments were done using CARA (http://cara.nmr.ch).
Saturation Transfer Difference NMR of TNRC6B Peptides and Argonaute 2
Saturation transfer difference (STD) NMR experiments [143] were performed on TNRC6B
peptides and Ago2, ranging in concentrations between 160-625 µM (peptides) and 2-3.5
µM (Ago2) (20 mM NaP (pH 6.5), 250 mM NaCl, 10% D2O) on a Bruker Avance III
500 MHz spectrometer equipped with a TXI cryogenic probe head at 298 K. Protein was
saturated by applying a series of 49 ms Gaussian pulses on the resonance frequency of
upfield shifted Ago2 methyl resonances (-1 ppm) with a total saturation time between
0.25 s and 15 s. An STD amplification factor, which resembles the relative binding affin-
ity of protons within a peptide, peptides of similar lengths, and different ligand:protein
ratios, is calculated according to Mayer et al. [144]. In short, intensities of the STD
NMR spectrum are divided by intensities of a reference 1D spectrum (with Gaussian
pulses being off-resonance) and multiplied by the ligand excess.
15N Relaxation Measurements of TNRC6 599-683
15N relaxation measurements of free TNRC6B 599-681 were conducted on a Bruker
Avance III 800 MHz NMR spectrometer equipped with a TXI cryogenic probe head at
298 K. R1, R2, and heteronuclear 15N1H NOEs were measured with gradient-enhanced,
sensitivity-enhanced pulse sequences described by Farrow et al. [61] . The 15N longitu-
dinal relaxation rates (R1) were measured with delays of 22, 43, 86, 173, 260, 346, 518,
691, 994, 1382, 1728, 1944, and 2160 ms, where delays of 22, 173, 346, 518, and 691 ms
were measured in duplicates. The 15N transverse relaxation rates (Rs) were measured
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with delays of 5, 10, 20, 40, 80, 100, 140, 150, 200, 300, 400, and 500 ms, where delays
of 5, 80, 100, and 200 ms were measured in duplicates. Peak volumes were calculated
by using the software PINT (in manuscript).
NMR Binding Studies of TNRC6B 599-683 and Argonaute 2
TNRC6B 599-683 and Ago2 binding was monitored by measuring chemical shift pertur-
bations and line width broadening. 1H 15N HSQC spectra were acquired of 15N-labeled
TNRC6B 599-683 with different protein ratios (1:0, 1:0.1, 1:1, TNRC6B599-681:Ago2).
Measurements were performed on a Bruker Avance III 800 MHz spectrometer equipped
with TXI cryogenic probe head at 298 K. Chemical shift perturbations, and peak vol-
umes as a measure of line width were analyzed using SPARKY [75], and atom-specific
chemical shift weighting was done according to Mulder et al. [151].
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Sequences TNRC6B and Ago2
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Secondary structure prediction TNRC6B
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Figure 5.0.1: Secondary structure prediction of TNRC6B. Secondary structure prediction was
performed with the program Quick2D [10] using different prediction algorithms for secondary structure
(SS), coiled-coils (CC), and disordered (DO) regions. Structural features are color coded.
Secondary structure prediction Ago2
Figure 5.0.2: Secondary structure prediction of Ago2. Secondary structure prediction was
performed with the program Quick2D 2006 using different prediction algorithms for secondary structure
(SS), coiled-coils (CC), and disordered (DO) regions. Structural features are color coded.
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Multiple sequence alignment TNRC6B
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Figure 5.0.3: Multiple sequence alignment of TNRC6B homologues. TNRC6B homologues
from selected organisms were aligned with MAFFT [105] using the Jalview software [216]. Conserved
sequence motifs are shaded in blue.
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Multiple sequence alignment Ago2
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Figure 5.0.4: Multiple sequence alignment of Ago2 homologues. Ago2 homologues from selected
organisms were aligned with MAFFT [105] using the Jalview software [216]. Conserved sequence motifs
are shaded in blue.
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Abbreviations
aa amino acid
Ago Argonaute
CD circular dichroism
CRISPR clustered regulatory interspaced short palindromic repeats
CSP chemical shift perturbation
cv column volume
C. elegans Caenorhabditis elegans
DLS dynamic light scattering
ds double stranded
DUF domain of unknown function
D. melanogaster Drosophila melanogaster
ELM european linear motif data bank
E. coli Escherichia coli
e.g. for example (exempli gratia)
GW-repeat glycine-tryptophan or tryptophan-glycine repeat
GST glutathione S-transferase
HCV hepatitis C virus
HSQC heteronuclear single quantum coherence
IPTG isopropyl-?-D-thiogalactopyranosid
LC low complexity
kDa kilo dalton
KD dissociation constant
MID middle
MS mass spectrometry
min minutes
miRNA microRNA
miRNP micro-ribonuleoprotein particle
mRNA messenger RNA
MVBs multivesicular bodies
NMR nuclear magnetic resonance
nt nucleotide
NOE nuclear overhauser effect
PABP poly(A)-binding protein protein
PAM2 poly(A)-binding protein-interacting motif 2
PAZ PIWI-Argonaute-Zwille
P/GW-bodies processing bodies
PBS phosphate buffered saline
PDB protein data bank
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Abbreviations
pf pyrococcus furiosus
pH potentia hydrogenii
piRNA PIWI-interacting RNA
PTM post translational modifications
pre-miRNA precursor miRNA
pri-miRNA primary miRNA
RISC RNA-induced silencing complex
RITS RNA-induced transcriptional silencing
RLC RISC loading complex
RNAi RNA interference
RNase ribonuclease
rpm revolutions per minute
RRM RNA recognition motif
RT room temperature
RH hydrodynamic radius
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEC size exclusion chromatography
siRNA small interfering RNA
SLiM short linear interaction motif
snoRNA small nucleolar RNA
ss single stranded
STD saturation transfer difference
TGS transcriptional gene silencing
TNRC6 trinucleotide repeat containing 6
TOCSY total correlation spectroscopy
UBA ubiquitin associated
UTR untranslated region
v/v volume per volume
wt wild typ
w/v weight per volume
Ala alanine
Arg arginine
Cys cystein
Gln glutamine
Gly glycine
His histidine
Ile isoleucine
Leu leucine
Lys lysine
Met methionine
Phe phenylalanine
Ser serine
Thr threonine
Trp tryptophan
Tyr tyrosin
Val valine
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